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Plasminogen Activator Inhibitor-1 (PAI-1) deﬁ ciency in mice is associated with impaired 
choroidal neo-vascularization (CNV) and tumoral angiogenesis. We investigated whether 
bone marrow-derived (BM) cells contribute to these two neo-vascularization processes 
regulated by PAI-1. We show here that the cellular source of PAI-1 differs in these 
pathological processes. PAI-1-/- mice grafted with BM-derived from Wild Type (WT) mice 
were able to support laser-induced CNV formation, but not skin carcinoma vasculari-
zation. Engraftment of irradiated WT mice with PAI-1-/- BM prevented CNV formation 
demonstrating the pivotal role of PAI-1 delivered by BM-derived cells. In sharp contrast, 
tumor vascularization is dependent to PAI-1 status of local resident cells, but not of 
BM cells. Differences between these two models could be related to the differential 
contribution of Placenta-like Growth Factor (PlGF) and Vascular Endothelial Growth 
Factor (VEGF), angiogenic factors involved in BM cell recruitment. Altogether, these 
data identify different cellular mechanisms contributing to PAI-1-regulated pathologi-
cal neo-vascularization. They shed new lights on what role individual cells play in the 
pathogenesis of ocular disease and cancer.
CAVEOLIN-1 PLAYS KEY ROLES IN THE REGULATION OF TUMOR ANGIOGENESIS: EVIDENCE FOR THE ACTIVATION OF 
MULTIPLE PRO-ANGIOGENIC SIGNALING PATHWAYS IN CAVEOLIN-DEFICIENT MICE.
Françoise Frérart, Julie DeWever, Pierre Sonveaux, *Agnès Noël, Chantal Dessy and Olivier 
Feron.
Unit of Pharmacology and Therapeutics (FATH 5349), University of Louvain (UCL) Medical 
School, B-1200 Brussels and *Laboratory of Tumor and Developmental Biology, Université de 
Liège, B-4000 Liège. (francoise.frerart@fath.ucl.ac.be)
Caveolae are 50- to 100-nm invaginated microdomains of the plasma membrane that function 
as regulators of signal transduction. Caveolin-1 belongs to a class of oligomeric structural 
proteins that are necessary for caveolae formation and has been involved in the regulation of 
several pathogenic processes, including tumor development. We have recently documented 
that caveolin-deﬁ cient mice exhibited a higher extent of tumor angiogenesis and we have 
therefore designed a series of experiments on more tractable models of angiogenesis to 
identify the determinants of this phenomenon. 
Using an ex vivo angiogenesis model, in which aortic explants from caveolin-1 deﬁ cient mice 
were cultured in 3D collagen type I gels in the presence of autologous serum, we showed that 
the absence of caveolin-1 was associated with a signiﬁ cantly higher extent of tube formation 
(than from wild-type mouse explants) (P<0.01, n=8). This observation was reproduced in an 
in vitro model of angiogenesis based on the ability of endothelial cells to form network when 
cultured on Matrigel (mixture of extracellular matrices extracted from tumors). Interestingly, 
further investigations revealed that the observed pro-angiogenic activity in caveolin-deﬁ cient 
mice arose both from the serum and from intrinsic characteristics of the vascular tissue of these 
mice. Accordingly, we documented that caveolin-1 deﬁ ciency was associated with an increased 
activity of the endothelial nitric oxide synthase (eNOS) and the consecutive accumulation of 
circulating nitric oxide-derived products in the blood of these animals. We further provided 
evidence that these NO derivatives exerted direct angiogenic activities, particularly in 
situations where hypoxia and acidosis were present. As for the tissue-speciﬁ c effects, we 
found that the lack of caveolin left the bFGF signaling pathway unopposed. This observation 
originally made in the aorta explant assay was conﬁ rmed with endothelial cells where the 
caveolin gene was down regulated using the siRNA technology or with endothelial cells directly 
derived from caveolin-deﬁ cient mice. Accordingly, caveolin deﬁ ciency was shown to promote 
ERK activation downstream bFGF stimulation and to prevent bFGF receptor internalization, 
thereby accounting for a constitutive activation of this signaling pathway.
 In conclusion, this study has identiﬁ ed key roles played by caveolin in the 
regulation of angiogenesis. That the lack of caveolin leads to the activation of signaling 
pathways involving key pro-angiogenic actors such as nitric oxide and bFGF opens interest-
ing therapeutic perspectives wherein the recombinant expression of caveolin could dampen 
tumor angiogenesis and thereby limits tumor growth.
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CAVEOLIN-1 IS CRITICAL FOR THE MATURATION OF TUMOR BLOOD VESSELS THROUGH THE REGULATION OF BOTH ENDOTHELIAL TUBE 
FORMATION AND PERICYTE COVERAGE.
Julie De Wever, Françoise Frérart, Caroline Bouzin, *Christine Baudelet, *Réginald Ansiaux, *Bernard Gallez, 
Chantal Dessy and Olivier Feron.
Unit of Pharmacology and Therapeutics (FATH 5349) and *Laboratory of Biomedical Magnetic Resonance, 
University of Louvain (UCL) Medical School, B-1200 Brussels, Belgium. (julie.dewever@fath.ucl.ac.be)
Extravasation of plasma proteins from tumor blood vessels accounts for the formation of a provisional 
matrix acting as a scaffold for proliferating and migrating endothelial cells during angiogenesis. In normal 
vascular beds, the structural protein caveolin directly participates in transcytosis (through caveolae-derived 
channel formation or shuttling vesicles) and in paracellular NO-mediated permeability (through the allosteric 
modulation of the endothelial nitric oxide synthase). Here, we used caveolin-deﬁ cient mice (cav-/-) and 
wild-type animals (cav+/+) to track the role of caveolin/caveolae in the regulation of tumor (B16 melanoma) 
blood vessel permeability. 
We ﬁ rst used radio-iodinated bovine serum albumin injection to get a global view of microvascular permeability 
in tumor-bearing mice of either caveolin genotype (-/- and +/+). We found that in cav-/- mice, albumin was 
more rapidly cleared from the circulatory system and accumulated more extensively in skeletal muscles. 
However, in the tumors, no difference in albumin extravasation was observed according to the caveolin 
genotype. Tumor immunostaining for ﬁ brinogen conﬁ rmed that the extent of macromolecule extravasation 
around small tumor blood vessels was not different in cav+/+ and cav-/- mice. Of note, however, more diffuse 
area of ﬁ brinogen staining could be detected around large vessels in cav-/- mice. The wick-in-needle technique 
revealed a net increase in interstitial ﬂ uid pressure (IFP) in tumor-bearing cav-/- mice (17.4 ± 0.1 vs 11.0 ± 
0.8 mmHg in cav+/+ mice; n=6). Search for immune cell inﬁ ltration or ﬁ broblast proliferation in cav-/- mice, 
with CD11b and CD90 antibodies, respectively, did not lead to the identiﬁ cation of differences supporting 
the IFP increase. In cav+/+ mice, however, ﬁ broblasts could be found in signiﬁ cantly larger amounts around 
blood vessels. This observation prompted us to examine the pericyte coverage of tumor blood vessels with 
an antibody directed against alpha-smooth muscle actin (SMA). Interestingly, while in cav+/+, we found a 
homogenous distribution of microvessels exhibiting the double CD31 and SMA staining across the tumor, cav-
/- mice revealed two very distinct vessel populations. At the periphery, we found very large vessels whereas the 
centre of the tumor presented a very dense population of small microvessels. Moreover, in both vessel types, 
the pericyte coverage (SMA positive staining) was either absent or very limited, but in all cases, signiﬁ cantly 
less developed than in Cav+/+ tumors.
To further explore this apparent defect in vessel maturation, we examined the endothelial and the ﬁ broblast-
like/pericyte outgrowth from aorta rings issued from both cav+/+ and cav-/- mice. The linearity of endothelial 
tubes outgrown from the aorta rings allowed to discriminate the proportion of corresponding DAPI-stained 
nuclei from the more dispersed ones associated to ﬁ broblast-like cells. Accordingly, we found that Cav-/- aorta 
rings gave rise to 1.5-fold more endothelial tubes than Cav+/+ mice (P<0.01) but that the number of ﬁ broblast-
like cells was dramatically reduced (13.3 ± 2.0 vs 25.4 ± 3.5 per microscopic ﬁ eld in Cav+/+; P<0.01, n=10).
Altogether, these data indicate that caveolin regulates angiogenesis but also the recruitment of pericytes to 
neo-formed endothelial tubes. Caveolin appears therefore as an important control point for the maturation of 
tumor blood vessels and the regulation of IFP and can be viewed as a new target for diagnostic or therapeutic 
strategies.
THE EXTRACELLULAR FRAGMENT OF N-CADHERIN STIMULATES ANGIOGENESIS AND MIGRATION AND INVASION OF 
CELLS
Lara Derycke, Elisabeth Van Aken and Marc Bracke
Laboratory of Experimental Cancerology, Univeristy Gent, University Hospital Gent, P7, De 
Pintelaan 185, 9000 Gent, Belgium
Lara.derycke@UGent.be
A cell becomes cancerous as a result of essential alterations in its physiology: limitless 
replicative potential, induction of angiogenesis and acquisition of invasive and metastasizing 
potential. The processes of both angiogenesis and invasion consist of the following aspects: 
loss of cell-cell contacts, gain in proteolytic activity and increased directional migration. The 
cadherins, transmembrane calcium-dependent adhesion molecules, play an important role in 
these processes. In a number of epithelial tumors the switch from E- (epithelial) to N- (neural) 
cadherin is a well described phenomenon. As a result the cells change from an epithelioid to a 
ﬁ broblast-like phenotype and become more invasive. In the microenvironment of the cancer 
cells proteases are secreted which are responsible for the shedding of the extracellular domain 
of N-cadherin, named soluble N-cadherin. N-cadherin is also expressed by endothelial cells and 
pericytes and plays a role in angiogenesis. Soluble N-cadherin is still functional: it stimulates 
neurite outgrowth. However the possible inﬂ uence of soluble N-cadherin on endothelial and 
cancer cell function and its signalling pathway are not well investigated.
RESULTS: We found that soluble N-cadherin is produced by all N-cadherin positive cells and 
that the cleavage could be stimulated by the use of plasmin, a serine protease. As a model 
for our experiments we are using sarcoma cells transfected or not with chicken N-cadherin, 
and human endothelial cells. Human soluble N-cadherin was puriﬁ ed and used to treat cells 
in different migration assays. We could prove that soluble N-cadherin stimulates the cancer 
cells to migrate in the wound healing assay and to invade in the collage type I assay. Soluble 
N-cadherin stimulates angiogenesis and the histidine-Alanine-Valine-(HAV) sequence is 
important for this effect. The stimulatory effect could be inhibited by using the ﬁ broblast 
growth factor receptor (FGFR) inhibitor PD173074. Soluble N-cadherin interferes with the 
N-cadherin –FGFR complex and activates the mitogen activated protein kinase (MAPK) 
signalling pathway.
CONCLUSION: Soluble N-cadherin stimulates cancer cells to migrate and invade and 
stimulates angiogenesis.
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TUMOR RADIOSENSITIZATION BY ANTI-INFLAMMATORY DRUGS : EVIDENCE FOR A NEW MECHANISM INVOLVING 
THE OXYGEN EFFECT.
Nathalie Crokart, Kim Radermacher, Bénédicte F. Jordan , Christine Baudelet, 
Gregory O. Cron, Vincent Grégoire, Nelson Beghein, Caroline Bouzin, Olivier Feron, 
and Bernard Gallez.
Laboratory of Biomedical Magnetic Resonance, Avenue Mounier 73, Université 
Catholique de Louvain, B-1200 Brussels, Belgium - gallez@cmfa.ucl.ac.be
We hypothesized that nonsteroidal anti-inﬂ ammatory drugs (NSAIDs) may enhance 
tumor radiosensitivity by increasing tumor oxygenation (pO
2
), via either a decrease in 
the recruitment of macrophages or from inhibition of mitochondrial respiration. The 
effect of four NSAIDs (diclofenac, indomethacin, piroxicam, NS-398) on pO
2
 was studied 





30 min after administration), perfusion, oxygen consumption and radiation sensitivity 
were studied. Local pO
2
 measurements were performed using electron paramagnetic 
resonance (EPR). Tumor perfusion and permeability measurements were assessed by 
dynamic contrast-enhanced magnetic resonance imaging. The oxygen consumption rate 
of tumor cells after in vivo NSAID administration was measured using high frequency 
EPR. Tumor-inﬁ ltrating macrophage localization was performed with immunohisto-





, tumor perfusion decreased, indicating that the increase in pO
2
 was not caused 
by an increase in oxygen supply. Also at t
max
, global oxygen consumption decreased 
but the amount of tumor-inﬁ ltrating macrophages remained unchanged. Our study 
strongly indicates that the oxygen effect caused by NSAIDs is primarily mediated by 
an effect on mitochondrial respiration. When irradiation (18 Gy) was applied at t
max
, 
the tumor radiosensitivity was enhanced (regrowth delay increased by a factor of 1.7). 
These results demonstrate the potential utility of an acute administration of NSAIDs 
for radiosensitizing tumors, and shed new light on the mechanisms of NSAID radiosen-
sitization. These results also provide a new rationale for the treatment schedule when 
combining NSAIDs and radiotherapy.
REVERSAL OF TEMPORAL AND SPATIAL HETEROGENEITIES IN TUMOR PERFUSION IDENTIFIES THE TUMOR VASCULAR TONE 
AS A TUNABLE PARAMETER TO IMPROVE DRUG DELIVERY.
Philippe Martinive, Julie DeWever, Caroline Bouzin, *Christine Baudelet, Pierre Sonveaux, 
§Vincent Grégoire, *Bernard Gallez and Olivier Feron.
Unit of Pharmacology and Therapeutics (FATH 5349), *Laboratory of Biomedical Magnetic 
Resonance; §Center for Molecular Imaging and Experimental Radiotherapy, University of Louvain 
(UCL) Medical School, B-1200 Brussels, Belgium. (philippe.martinive@imre.ucl.ac.be)
The maturation of the tumor vasculature implies the recruitment of pericytes covering 
and protecting the endothelial tubes from a variety of stresses including anti-angiogenic 
drugs. Mural cells also provide mature tumor blood vessels with the ability to either relax 
or contract in response to substances present in the tumor microenvironment. The observed 
cyclic alterations in tumor blood ﬂ ow (TBF) and the associated deﬁ cit in chemotherapeutic 
drug delivery could arise from the inﬂ uence of such vasomodulators. 
To challenge this hypothesis, we focused our work on endothelin-1 (ET-1) which, besides its 
largely ubiquitous, autocrine effects on tumor cell growth, is a powerful vasoconstrictor. We 
ﬁ rst documented that an ET
A
 receptor antagonist could induce the relaxation of microdis-
sected tumor arterioles, and selectively and quantitatively increase TBF in experimental 
tumor models. We then combined dye staining of functional (perfused) vessels, ﬂ uorescent 
microspheres-based mapping and dynamic contrast enhanced-magnetic resonance imaging 
(DCE-MRI) to identify TBF heterogeneities and examine the reversibility of such phenomenon. 
We found that administration of ET
A
 receptor antagonist could indeed acutely reduce the 
extent of underperfused tumor areas, thereby proving the key role of vessel tone variations 
in the TBF heterogeneities. Importantly, we also provided evidence that the ET
A
 antagonist 
administration could, despite an increase in tumor interstitial ﬂ uid pressure, improve the 
access of the contrast agent used in DCE-MRI and of conventional chemotherapy to the tumor 
compartment. We showed that the combinatory administration of cyclophosphamide with 
the ET
A
 antagonist led to a signiﬁ cant increase in tumor growth delay when using low doses 
of cyclophosphamide and even to the tumor control when higher doses were used (vs either 
treatment given separately). 
In conclusion, we report here that tumor endogenous ET-1 production largely participates in 
the temporal and spatial variations in TBF and that ET
A
 antagonist administration may wipe 
out such heterogeneities, thereby eliciting an adjuvant strategy to improve the delivery of 
chemotherapeutic drugs to the tumor.
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BLOOD AND LYMPH VESSEL INVASION IN BREAST CANCER: A PROSPECTIVE HISTOMORPHOMETRICAL STUDY IN 101 PATIENTS
Gert Van den Eynden, Steven Van Laere, Ilse Van der Auwera, Cecile Colpaert, Peter van Dam, Luc 
Dirix, Peter Vermeulen and Eric Van Marck
Translational Cancer Research Group Antwerp (Lab Pathology University Antwerp/University Hospital 
Antwerp, Edegem; Oncology Center, General Hospital St.-Augustinus, Wilrijk), Antwerp, Belgium
Introduction: Blood (BVI) and lymph vessel invasion (LVI) are the histological correlates of the ﬁ rst 
steps of haematogenous and lymphatic metastasis in solid tumours. The discovery of new lymphatic 
endothelium speciﬁ c markers such as D2-40, makes it possible to distinguish between blood and 
lymph vessels. Therefore, the aim of this study was to quantify and compare blood and lymph vessel 
invasion in a consecutive series of breast cancer patients.
Materials and Methods: Three consecutive 5 µm sections of all formalin-ﬁ xed parafﬁ n embedded (FFPE) 
tissue blocks of 101 consecutive breast cancer resection specimens were (immuno)histochemically 
stained with haematoxylin-eosin and with antibodies against CD34 (pan-endothelium) and D2-40 
(lymphatic endothelium). On every slide all vessels containing single tumour cells or tumour cell 
emboli were marked, and based on the immunohistochemical staining pattern, vascular invasion 
was assessed as LVI (CD34 or /D2-40 ) or BVI (CD34+/D2-40 ). LVI and BVI were assessed 
as intra- (being in contact with tumour cells or desmoplastic stroma) or peritumoral. The number 
of intra- and peritumoral vessels with LVI and BVI per patient was counted as well as the number of 
tumour cells in every vessel. Results were correlated with clinico-pathological variables, the growth 
pattern of the tumour and the presence of a ﬁ brotic focus.
Results: In total 3390 (intra: 718, peri: 2672) vessels with LVI and 143 (intra: 80, peri 63) vessels with 
BVI were detected. The median number of FFPE blocks investigated per patient was 4. The number 
of patients with LVI was higher then the number of patients with BVI (LVI: 70.3% (intratumoral: 
33.7% and peritumoral: 61.4%); BVI: 38.6% (intratumoral: 28.7% and peritumoral: 25.7%)). The 
absence/presence of BVI and LVI was concordant with the absence/presence of vascular invasion 
determined on the haematoxylin-eosin slides in 63.4% (p=0.002) and 77.2% (p<0.001) of cases, 
respectively. An association was found between the presence of intratumoral LVI (p=0.04) or 
peritumoral LVI (p=0.001) and axillary lymph node involvement. For BVI no association was found 
with axillary lymp node status.
Intra- and peritumoral BVI were strongly associated (concordance: 77.2% ,p<0.001), while for 
intra- and peritumoral LVI only a trend was found (concordance: 54.5%, p=0.08). LVI was associated 
with BVI, intratumorally (p=0.02), not peritumorally (p=0.16). Furthermore, more intratumoral LVI 
(p=0.05) and BVI (p=0.02) were found in tumours with an expansive growth pattern; more intra- and 
peritumoral LVI and BVI (p<0.05) were found in high grade tumors and tumors with a ﬁ brotic focus. 
The size of the intravascular tumor embolus was larger in peritumoral then in intratumoral vessels 
(p<0.001), both for LVI and BVI.
Conclusion: Our data demonstrate that it is possible to reliably distinguish BVI and LVI in breast 
cancer resection specimens using recently characterized speciﬁ c lymphatic endothelium markers. 
This is important to study the contribution of both processes to the metastatic cascade in breast 
cancer. Furthermore, our data sustain the hypothesis that haematogenous and lymphatic metastasis 
are speciﬁ c but complementary pathways.
IMPACT OF VEGF-DEPENDENT ANGIOGENESIS ON THE LYMPHOCYTE-ENDOTHELIUM INTERACTIONS: IDENTIFICATION OF NITRIC 
OXIDE AS A CONTROL POINT OF ENDOTHELIAL CELL ANERGY.
Caroline Bouzin, Agnès Brouet, Marie Palumbo, Joelle De Vriese and Olivier Feron.
Unit of Pharmacology and Therapeutics, University of Louvain Medical School, 53 Avenue E. Mounier, 
UCL-FATH 5349, B-1200 Brussels (bouzin@fath.ucl.ac.be).
Cytolytic T lymphocytes play crucial roles in host defense against tumours. Accordingly, several studies 
have shown that leukocyte inﬁ ltration can positively inﬂ uence the prognosis of cancer. However it 
is also known that tumour cells may evade or resist immune responses at multiple levels within the 
effector-target interaction. In this study, we postulated that one mode of resistance could be a defect 
in the leukocyte-vessel wall interactions. The nature of the endothelial cells lining tumor blood vessels 
is, indeed, different from the endothelium of healthy tissues: tumor angiogenesis implies for instance 
that endothelial cells are either proliferating or at least are under the inﬂ uence of many cytokines 
while endothelial cells are largely quiescent in mature vascular beds of healthy organs. 
To mimick the impact of the tumor microenvironment on the endothelium, we have exposed endothe-
lial cells to both the cytokine TNF-a and the pro-angiogenic factor VEGF. We have then examined the 
ability of lymphoid Jurkat cells or freshly isolated human CD8 to adhere to the “activated” endothelial 
cells. A dramatic inhibition of adhesion was observed with both cell populations (tracked by pre-loading 
them with calcein as a ﬂ uorophore). Interestingly, short (30 min) and long (16h) VEGF exposures led 
to a similar reduction in the adhesion of immune cells. Although RT-PCR analyses revealed a slight 
decrease in the mRNA expression of major adhesion molecules including selectins and ICAM, the 
expression of these adhesion molecules at the cell surface was not signiﬁ cantly altered. Immunocy-
tochemistry experiments eventually revealed that VEGF impaired the clustering of these adhesion 
molecules. Caveolae are plasmalemmal invaginations that have been proposed to participate in 
the concentration of adhesion molecules and we therefore examined the impact of modifying the 
abundance of caveolin (the structural protein of caveolae) on the ability of VEGF to alter the adhesion 
process. Accordingly, overexpression of caveolin-1 in endothelial cells could overcome VEGF-mediated 
inhibition of adhesion whereas transfection of siRNA directed against caveolin-1 could reduce the 
TNF-a-dependent increase in adhesion. Still, we failed to document a co-localization of caveolin-1 
and adhesion molecules such as ICAM in endothelial cells, thereby excluding a role of caveolae per 
se in the clustering process. Instead, we identiﬁ ed the NO release by the endothelial NO synthase 
(eNOS) as the main target of altering caveolin abundance (eg, an increase in caveolin reducing the 
NO production and inversely). We conﬁ rmed this observation by using the NOS inhibitor L-NAME that 
reversed the inhibitory effects of VEGF on lymphocyte adhesion, thereby recapitulating the effects 
of caveolin overexpression. We also found that the NO-mediated rearrangement of the cytoskeleton 
could directly account for the VEGF-induced alteration in the adhesion molecules clustering process 
needed to ensure efﬁ cient lymphocyte recruitment.
In conclusion, this study provides new insights on the mechanisms leading to the anergy of endothelial 
cells in tumor blood vessels. Our work also opens new perspectives for anti-angiogenic strategies that 
could act as adjuvant approaches to immunotherapy.
BOTULINUM TOXIN POTENTIATES CANCER RADIOTHERAPY AND CHEMOTHERAPY
Réginald Ansiaux, Christine Baudelet, Greg.O Cron, Jérôme Segers, Chantal Dessy, 
Philippe Martinive, Julie De Wever, Julien Verrax, Valérie Wauthier, Nelson Beghein, 
Vincent Grégoire, Pedro Buc Calderon , Olivier Feron and Bernard Gallez
Laboratory of Biomedical Magnetic Resonance, Avenue Mounier 73, Université 
Catholique de Louvain, B-1200 Brussels, Belgium - gallez@cmfa.ucl.ac.be
Structural and functional abnormalities in the tumor vascular network are considered 
factors of resistance of solid tumors to cytotoxic treatments. To increase the efﬁ cacy 
of anti-cancer treatments, efforts must be made to ﬁ nd new strategies for transiently 
opening the tumor vascular bed in order to alleviate tumor hypoxia (source of 
resistance to radiotherapy) and improve the delivery of chemotherapeutic agents. 
We hypothesized that Botulinum Neurotoxin type A (BoNT-A) could interfere with 
neurotransmitter release at the perivascular sympathetic varicosities, leading to 
inhibition of the neurogenic contractions of tumor vessels and therefore improving 
tumor perfusion and oxygenation. 
To test this hypothesis, BoNT-A was injected locally into mouse tumors (ﬁ brosarcoma 
FSaII, hepatocarcinoma TLT) and electron paramagnetic resonance (EPR) oximetry was 
used to monitor pO
2
 in vivo repeatedly for four days. Additionally, contrast-enhanced 
magnetic resonance imaging (MRI) was used to measure tumor perfusion in vivo. 
Finally, isolated arteries were mounted in wire-myograph to monitor speciﬁ cally 
the neurogenic tone developed by arterioles that were co-opted by the surrounding 
growing tumor cells. 
Using these tumor models, we demonstrated that local administration of BoNT-A (2 
sites, dose 29 U.kg-1) substantially increases tumor oxygenation and perfusion, leading 
to a substantial improvement in the tumor response to radiotherapy (20 Gy of 250 kV 
RX) and chemotherapy (cyclophosphamide 50mg/kg). This observed therapeutic gain 
results from an opening of the tumor vascular bed by BoNT-A, since we demonstrated 
that BoNT-A could inhibit neurogenic tone in the tumor vasculature.
In conclusion, the opening of the vascular bed induced by BoNT-A offers a way to 
signiﬁ cantly increase the response of tumors to radiotherapy and chemotherapy.
IDENTIFICATION OF HIF-1 INDEPENDENT PROTEINS OVEREXPRESSED UNDER HYPOXIA IN TUMOR CELLS.
Pyr dit Ruys Sébastien†*, Delaive Edouard, Dieu Marc, Raes Martine, Michiels Carine†.
† Laboratoire de Biochimie et Biologie cellulaire, University of Namur, 61 rue de Bruxelles, 
B-5000 Namur, Belgium.
* E-mail: sebastien.pyrditruys@fundp.ac.be
Our work takes place in the global effort that aims to have a better knowledge of the 
mechanisms by which tumor cells can adapt to low oxygen tension during cancer develop-
ment. It has been shown that a hypoxic area rapidly develops in the center of a tumor due 
to the reject of the preexisting blood vessels to the peripheric area of the growing tumor 
mass. This hypoxic area is responsible for biochemical modiﬁ cations within tumor cells that 
allow them not only to adapt to hypoxia, but also render them more resistant to chimio or 
radiotherapy treatments. The master regulator of this adaptive response is HIF-1 (Hypoxia 
Inducible Factor-1), which controls 60% to 80% of the genes that allow adaptation to hypoxia. 
HIF-1 is a heterodimeric transcription factor made up of two subunits, HIF-1α and ARNT (Aryl 
Receptor Nuclear Translocator). However, if HIF-1 is important for the adaptive response to 
hypoxia, it does not explain all the complexity of this response and the other factors involved 
still wait to be identiﬁ ed. 
In order to point up HIF-1 independent mechanisms triggered under hypoxia, we decided 
to use, for comparative analysis, the murine cell line Hepa C1 and its counterpart Hepa C4, 
which lacks the ARNT subunit. A proteomic 2-D gel using the Cye Dye (DIGE) technique 
allowed us, after stimulation (normoxia versus hypoxia) of 3 independent cell cultures, to 
highlight different proteins that are responsive to hypoxia. These proteins were sorted into 
two groups: proteins that are overexpressed under hypoxia in both cell lines, and cell line-
speciﬁ c proteins. For the ﬁ rst group, the most striking observation is that all these proteins 
are up-regulated under hypoxia, there is no down-regulated proteins. Moreover, the fold of 
induction in Hepa C4 cell line is often bigger than in the Hepa C1 counterpart. This could be 
interpreted as a part of a compensatory mechanism. Several such proteins were identiﬁ ed by 
mass spectrometry. They correspond, for example, to Signal Transducing Adaptator protein 
2, Ribonucleotide Reductase M1 or Elongation Factor B. For the second group, we focused 
on proteins overexpressed under hypoxia in Hepa C4, whose induction is HIF-1 independent. 
They are mostly cytoskeleton proteins like lamin A/C, vimentin, cortactin or dynein, and they 
are up-regulated or biochemically modiﬁ ed during hypoxia in Hepa C4 cells. We also pointed 
out the up-regulation of the chaperonine TCP-1 epsilon, which is known to interact with 
cytoskeleton elements. Their potential involvement into the adaptive responses to hypoxia 
are currently under investigation, but they may play a role in cell migration that could be 
enhanced under hypoxia.
All these results evidenced several new HIF-1-independent proteins which are involved in 
the adaptive response to hypoxia. These proteins may represent new attractive targets for 
cancer therapy.
Acknowledgments : This work is supported by a Télévie grant
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IS URINE A FEASABLE AND RELIABLE TOOL TO SCREEN FOR HPV?
K. D’Hauwers1, C. E. Depuydt2, M. Stalpaert2, A.J. Vereecken2, J. Bogers2, 3, J.J. Wyndaele1, W. 
Tjalma4
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Abstract
Aim: Human Papillomavirus (HPV)-infection is the most common sexual transmitted disease 
(STD) of viral aetiology. At least 30 types of HPV are known to infect the ano-genital region. 
Low-risk types (6, 11) are responsible for rather benign conditions like genital warts while 
high-risk types (16, 18, 31, 33, 45) are related with ano-genital cancer like cervical and penile 
carcinomas. Cervical cytology can detect (pre)malignant lesions in asymptomatic women. 
In abnormal smears it is recommended to perform Polymerase Chain Reaction (PCR)-testing 
for HPV-DNA, which is the golden standard. It can be used for screening, diagnostic and 
follow-up purposes. For males there is no golden standard at all. For both sexes a cheap and 
reliable method should be found; as well for diagnostics, as for screening and follow up. Testing 
urine for HPV could be a possibility since screening kits for other STD’s are available using 
PCR-testing of ﬁ rst voided urine specimens (FVU). To evaluate if HPV testing on urine is a 
reliable technique, ß-globin concentration and HPV positivity for oncogenic HPV types was 
measured by real time PCR in FVU and compared with the ﬁ ndings in swabs of the glandular 
urethra and of the glans penis. The concentration of ß-globin and HPV positivity in FVU of 
males and females was also compared.
Methods: First voided urine (FVU) of 30 males and 31 females and urethra-glandular brushes 
of 12 men were examined for the presence of ß-globin (indicative for the amount of DNA). 
Then HPV-DNA was searched using PCR.
Results: The percentage of FVU-samples with detectable ß-globin concentration did not 
differ between men (66.7%) and women (71%). Where the Cervex brush was used to collect 
glandular-urethral cells, ß-globin was detected in 100% of the cases. Correspondingly the 
mean absolute concentration of DNA (ng/µl) is signiﬁ cantly higher in the brushes: 0.9985 ng/µl 
versus 0.0207 ng/µl ( FVU men) and 0.0916 ng/µl (FVU females). This results in HPV-positivity 
in 66.7% of the brushes versus 0% of FVU in males and 4.5% of FVU in females.
Conclusion: FVU in men (male and female) is not a good tool, nor for diagnostics, nor for 
screening. While the presence of ß-globin is moderately high, the absolute amount of DNA 
is to low to detect the presence of HPV. 
ß-globin-positivity of urethral swabs is 100%, showing an higher absolute concentration of 
DNA, leading to a higher detection rate of HPV. 
NF-KAPPAB SIGNATURE OF INFLAMMATORY BREAST CANCER BY CDNA MICROARRAY VALIDATED BY QUANTITATIVE REAL-TIME RT-PCR AND IMMUNOHIS-
TOCHEMISTRY.
Steven Van Laere, Ilse Van der Auwera, Gert Van den Eynden, Véronique Huygelen, Hilde Elst, Peter Van Dam, Eric Van Marck, 
Peter Vermeulen and Luc Dirix.
Translational Cancer Research Group
(Lab Pathology University of Antwerp and Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium)
Inﬂ ammatory Breast Cancer (IBC) is the most aggressive form of locally advanced breast cancer with high metastatic potential. 
Most patients at diagnosis have lymph node involvement and 1/3 of the patients have metastasis in distant organs. In a previous 
study we demonstrated that IBC is a different form of breast cancer compared to non-IBC by cDNA microarray analysis. A list 
of 756 genes with signiﬁ cant gene expression differences between IBC and non-IBC was identiﬁ ed. Unsupervised hierarchical 
clustering separated IBC from non-IBC. A set of 50 discriminator genes was identiﬁ ed in a learning group of tumour samples 
and was successful in diagnosing IBC in a validation group of samples (accuracy of 88%). In depth functional analysis revealed 
the presence of a high number of NF-kappaB target genes with elevated expression in IBC versus non-IBC. This led to the 
hypothesis that NF-kappaB is an important factor, contributing to the development of IBC. The aim of the present study was 
to further investigate the role of NF-kappaB in the pathogenesis of IBC. Therefore, we analyzed the expression of 8 NF-kappaB 
target genes with signiﬁ cant differences (at least 3 fold) in gene expression levels between 9 IBC and 9 non-IBC specimen, 
measured by cDNA microarray analysis (Van Laere et al, Breast Cancer Res Treat, in press). Additionally, we stained 44 IBC and 
45 non-IBC tissue sections using antibodies against the NF-kappaB family member RelA, RelB, cRel, NFkB1 and NFkB2. We 
found a signiﬁ cant overexpression for all NF-kappaB target genes in IBC compared to non-IBC. Furthermore, we found strong 
correlations between all NF-kappaB target genes, indicative for a common transcriptional regulation. In addition we found 
a statistically elevated number of stained nuclei in IBC as compared to non-IBC for RelB (p=0.038) and NFkB1 (p<0.001). 
Transcriptionally active NF-kappaB dimers, composed of speciﬁ c combinations of NF-kappaB family members, were found in 
17/44 IBC specimens compared to 2/45 non-IBC specimens using a 50% cut-off value for discrimination between absence 
and presence for each NF-kappaB family member (p<0,001). The same analysis was repeated using cut-off values of 40% and 
30%. We identiﬁ ed respectively 23/44 and 32/44 IBC specimen with transcriptionally active NF-kappaB dimers compared 
to respectively 7/45 and 16/45 non-IBC specimen with transcriptionally active NF-kappaB dimers (Pearson χ2, p<0.001 and 
p<0.001 respectively). In order to validate these results we looked for gene expression differences for NF-kappaB target genes 
between tumours with transcriptionally active and inactive NF-kappaB dimers. Independent of the chosen cut-off value, 
we found signiﬁ cant gene expression differences for most of the NF-kappaB target genes with higher median expression of 
NF-kappaB target genes in tumours with transcriptionally active NF-kappaB dimers. These results clearly demonstrate that 
NF-kappaB, and particularly the RelB/NFkB1 dimer, is activated more often in IBC compared to non-IBC. In conclusion, the 
NF-kappaB transcription factor pathway probably contributes to the phenotype of IBC. We are currently performing NF-kappaB 
DNA-binding experiments to further validate the NF-kappaB signature of IBC.
Presenting author:  Steven Van Laere





IDENTIFICATION OF CELL-OF-ORIGIN BREAST TUMOUR SUBTYPES IN INFLAMMATORY BREAST CANCER BY GENE EXPRESSION PROFILING.
Steven Van Laere, Gert Van den Eynden, Ilse Van der Auwera, Véronique Huygelen, Melanie Vandenberghe, Hilde 
Elst, Peter Van Dam, Peter Vermeulen, Luc Dirix and Eric Van Marck.
Translational Cancer Research Group
(Lab Pathology University of Antwerp and Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium)
Inﬂ ammatory Breast Cancer (IBC) is an aggressive form of locally advanced breast cancer with high metastatic 
potential. Most patients have lymph node involvement at the time of diagnosis and 1/3 of the patients have distant 
metastases. In a previous study, we demonstrated that IBC is a distinct form of breast cancer in comparison with 
non-IBC (Van Laere et al, Breast Cancer Res Treat, 2005). The aim of this study was to investigate the presence of 
the different molecular subtypes, described by Sorlie et al (PNAS,2003) in our data set of 16 IBC and 18 non-IBC 
specimen. Therefore, we selected an “intrinsic gene set” of 144 genes, present on our cDNA chips and common 
to the “intrinsic gene set” deﬁ ned by Sorlie et al (PNAS, 2003). This set of genes was tested for performance in 
the Norway/Stanford data set by unsupervised hierarchical clustering. 84% Of the samples belonging to this set 
clustered in the same manner as described in the original manuscript. Expression centroids were then calculated 
for the core members of each of the 5 subclasses in the Norway/Stanford data set and used to classify our own 
specimens by calculating spearman correlations between each sample and each centroid. We found a higher amount 
of basal-like and ErbB2-overexpressing tumours and a lower amount of luminal A, luminal B or normal-like tumours 
in IBC as compared to non-IBC (ErbB2+/Basal: IBC:8, non-IBC:3; LumA/LumB/Norm: IBC:8, non-IBC:15; Pearson 
Chi-Square, p=0.036). Our ﬁ ndings were in good agreement with protein expression data for Estrogen Receptor 
(ER+; ErbB2+/Basal: 2/11, LumA/LumB/Norm: 12/23, p=0.063) and Cytokeratin 5/6, a representative marker for 
the basal-like subtype (CK5/6+; basal: 6/7, non-basal: 4/13, p=0.057). The classiﬁ cation was conﬁ rmed by using 
an alternative unsupervised hierarchical clustering method (average-linkage clustering). The robustness of this 
classiﬁ cation was conﬁ rmed by unsupervised hierarchical clustering using an alternative gene set of 141 genes 
related to the cell-of-origin subtypes, selected using a discriminating score and 200 iterative random permutations 
producing less then 5 false positives. Compared to the data published by Bertucci et al (Cancer Research, 2005), 
we found a higher amount of basal and Her2 overexpressing tumours and a lower amount of luminal A, luminal 
B or normal-like tumours in IBC as compared to non-IBC (Her2/Basal: IBC:8, non-IBC:3; LumA/LumB/Norm: IBC:8, 
non-IBC:15; Pearson Chi-Square, p=0.036). Furthermore, we found a signiﬁ cant difference in the amount of ER+ 
IBC specimen in the combined Luminal A, Luminal B and Normal-like clusters as compared to the corresponding 
cluster reported by Bertucci et al (respectively 4/8, 19/19, Fisher’s Exact Test; p=0.004). The presence of the same 
molecular cell-of-origin subtypes in IBC as in non-IBC does not exclude the speciﬁ c molecular nature of IBC. The 
molecular mechanisms involved in the biology of IBC are translated in gene sets, different from the ones used to 
deﬁ ne cell-of-origin subtypes. Therefore we suggest that IBC and non-IBC have to be regarded as separate entities 
with important diagnostic and therapeutic consequences. 
Presenting author:  Steven Van Laere





INFLAMMATORY BREAST CANCER: AT THE CROSS-ROADS OF NF-KAPPAB AND ESTROGEN RECEPTOR SIGNALING PATHWAYS.
Steven Van Laere, Ilse Van der Auwera, Gert Van den Eynden, Véronique Huygelen, Hilde Elst, Peter Van Dam, Eric Van Marck, 
Luc Dirix and Peter Vermeulen.
Translational Cancer Research Group
(Lab Pathology University of Antwerp and Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium)
Inﬂ ammatory Breast Cancer (IBC) is the most aggressive form of locally advanced breast cancer characterized by a high 
metastatic potential and poor patient outcome. In a previous study we demonstrated that IBC is a different form of breast 
cancer compared to non-IBC by cDNA microarray analysis. A list of 756 genes with signiﬁ cant gene expression differences 
between IBC and non-IBC was identiﬁ ed. Among these genes a large amount of NF-kappaB target genes was detected. The 
NF-kappaB signature in IBC was validated by Real-Time RT-PCR for 8 NF-kappaB target genes and by immunohistochemistry 
for all NF-kappaB transcription factor family members (RelA, RelB, cRel, NFkB1 and NFkB2). Recently, several studies have 
indicated a cross-talk between Estrogen Receptor (ER) and NF-kappaB signaling, resulting in the inhibition of NF-kappaB or ER 
dependent signaling. Since IBC is known to be more often ER negative compared to non-IBC, we hypothesize that the presence 
of the NF-kappaB signature in IBC can be explained by the interaction between both signaling pathways. To investigate this 
hypothesis we performed Real-Time RT-PCR on 17 IBC and 20 non-IBC specimens for ER alpha, ER beta and Progesterone 
Receptor (PR). The expression of NF-kappaB target genes, measured by Real-Time RT-PCR was correlated with gene and protein 
expression data for ER. Immunohistochemical data for transcriptionally active NF-kappaB dimers were correlated with IHC and 
gene expression data for ER and PR. As expected, relative gene expression of ER alpha en PR were elevated in non-IBC (median 
respectively 5,93 and 1,17) compared to IBC (median respectively 0,75 and 0,71) specimens, however only the difference in 
expression for ER alpha showed a trend towards signiﬁ cance (p=0,069 and p=0,68). Relative gene expression levels for ER 
beta was signiﬁ cantly elevated in IBC (median 1,46) compared to non-IBC (median 0,78) (p=0,013). The expression of all 
NF-kappaB target genes were signiﬁ cantly elevated in IHC ER- tumours compared to IHC ER+ tumours. The expression levels 
of all NF-kappaB target genes showed a signiﬁ cant inverse correlation with the expression level of ER alpha, whereas for PR 
inverse correlations were observed for only 3 NF-kappaB target genes. For ER beta gene expression, signiﬁ cant correlations 
were found with 5 NF-kappaB target genes. When analyzing the presence of transcriptionally active NF-kappaB dimers in IHC 
ER+ vs IHC ER- tumour specimens we found 16/49 ER- tumours and 3/40 ER+ tumours with transcriptionally active NF-kappaB 
(p<0,004). The median gene expression level for both ER alpha and PR is reduced in IHC NF-kappaB positive tumours (median 
respectively 0,68 and 0,50) compared to IHC NF-kappaB negative tumours (median respectively 4,41 and 1,31) (p=0,179 and 
p=0,304). The median relative gene expression level for ER beta is elevated in IHC NF-kappaB positive tumours (median 2,46) 
compared to IHC NF-kappaB negative tumours (median 0,79) (p=0,122). Altogether, these data suggest a cross-talk between 
ER signaling and NF-kappaB signaling in IBC with potential therapeutic implications. We are currently investigating an ER target 
gene signature in our data set of IBC and non-IBC specimens and ER DNA-binding assays will be performed. 
Presenting author:  Steven Van Laere
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INFLAMMATORY BREAST CANCER HAS A QUIESCENT FIBROBLAST GENE EXPRESSION SIGNATURE 
Gert Van den Eynden, Steven Van Laere, Ilse Van der Auwera, Cecile Colpaert, Peter van Dam, Luc Dirix, 
Peter Vermeulen and Eric Van Marck
Translational Cancer Research Group Antwerp (Lab Pathology University Antwerp/University Hospital 
Antwerp, Edegem; Oncology Center, GH St. Augustinus, Wilrijk) Belgium
Introduction : Chang et al. demonstrated that breast cancer and other solid tumours can be devided in two 
groups with different prognosis based on a wound healing gene expression proﬁ le, obtained by comparing 
quiescent and activated ﬁ broblasts (Chang et al. PLos Biology 2004 and PNAS 2005) . We investigated 
whether this wound healing signature could be found in the speciﬁ c and distinct gene expression proﬁ le 
of inﬂ ammatory breasts cancer (IBC) (Van Laere et al. Breast Cancer Res Treat, in press). 
Materials and Methods : A set was compiled of genes being part of the quiescent and activated ﬁ broblasts 
signature (Chang et al. Plos Biology 2004) that were also present on the cDNA microarrays used to 
compare IBC and non-IBC specimens (Van Laere et al. Breast Cancer Res Treat, in press). Its performance 
was tested on Chang’s dataset. A group op samples of quiescent and of activated ﬁ broblasts with the most 
homogenous gene expression were used to calculate the respective centroids. The power was tested. With 
this reduced gene set, IBC and non-IBC specimens were hierarchically clustered and correlations between 
gene expression of each IBC and non-IBC specimen and both centroids were calculated. The same analyses 
were performed after exclusion of proliferation-related genes (Chang et al. Plos Biology 2004)) 
Results : The compiled gene set consisted of 98 genes. Hierarchical cluster analysis perfectly separated 
quiescent and activated ﬁ broblast samples, validating its use on our IBC and non-IBC dataset. 15 and 18 
samples were used to calculate the quiescent and activated centroids in Chang’s dataset. All remaining 
samples of quiescent and activated ﬁ broblasts correlated to the quiescent and activated centroid, 
respectively: power 100%. Table 1 shows the results of the correlation analysis of IBC and non-IBC 
specimens with the centroids. When proliferation-related genes were excluded, 78 out of 98 genes were 
left. With this gene list, similar results were found. The differential expression of wound-healing genes in 
IBC and non-IBC is momentarily conﬁ rmed using real-time RT-PCR.
Discussion : Our results show that the gene signature of Chang et al. can differentiate between IBC 
and non-IBC and that IBC mostly shows a quiescent gene expression signature. These results again 
conﬁ rm that IBC is a distinct biological entity with a speciﬁ c gene expression signature. The quiescent 
expression phenotype could be correlated to the inﬁ ltrative growth pattern of IBC. In IBC, tumour cells 
indeed grow between pre-existing breast structures without destruction of the stroma or induction of 
a desmoplastic reaction.
Table 1
p = 0.006 (Sign + Non-Sign); p = 0.03 (Sign Only) IBC Non-IBC




Non-Signiﬁ cant 6 2




Non-Signiﬁ cant 4 8
REAL-TIME RT-PCR OF CD146 AND VE-CADHERIN MRNA TO DETECT CIRCULATING ENDOTHELIAL CELLS IN PERIPHERAL BLOOD OF PATIENTS 
WITH BREAST CANCER
Translational Cancer Research Group (Laboratory of Pathology University of Antwerp/University Hospital Antwerp, 
Edegem; Oncology Centre, General Hospital St-Augustinus, Wilrijk)
Ilse Van der Auwera, Hilde Elst, Veronique Huygelen, Steven Van Laere, Gert Van den Eynden, Peter van Dam, Peter 
Vermeulen, Luc Dirix and Eric Van Marck
Introduction: Angiogenesis is a fundamental process in tumour growth and metastatic dissemination. The number of 
circulating endothelial cells (CECs) in peripheral blood (PB) of patients with cancer reﬂ ects the amount of proceeding 
neoangiogenesis and can therefore be used as a surrogate marker to monitor antiangiogenic therapy. The standard 
quantiﬁ cation method of CECs is currently based on a complex four-color ﬂ ow cytometrical analysis. However, real-
time RT-PCR technology to quantify endothelial cell-speciﬁ c mRNA in PB samples has been shown to be a promising 
alternative approach. This study aimed to compare mRNA expression levels of endothelial-cell speciﬁ c markers (CD146 
and VE-cadherin) in PB of healthy volunteers and patients with breast cancer using real-time RT-PCR.
Methods: PB samples have been collected from 18 healthy volunteers and 18 metastatic breast cancer patients using 
the PAXgene Blood RNA System. RNA was subsequently isolated with the PAXgene Blood RNA isolation kit according 
to manufacturer’s instructions and reverse transcribed into cDNA with random primers. Real-time PCR analysis was 
performed with primers and TaqMan probes for both CD146 and VE-cadherin mRNA. Ct values were normalised for 
beta-actin mRNA expression and gene expression levels were calculated relative to a reference sample (RGE).
Results: VE-cadherin mRNA was increased in patients with breast cancer in comparison to healthy volunteers: the 
median VE-cadherin mRNA expression level in PB of healthy volunteers was 1.20 (range 0.50-4.18); while this was 
2.45 (range 0.69-25.80) for patients with breast cancer (p=0.040). However, the difference in CD146 mRNA expression 
levels between healthy volunteers and patients with breast cancer did not reach statistical signiﬁ cance: the median 
CD146 mRNA expression level in PB of healthy volunteers was 0.037 (range 0.020-0.058); while this was 0.058 
(range 0.013-0.488) for patients with breast cancer (p=0.077). CD146 and VE-cadherin mRNA expression levels were 
signiﬁ cantly correlated (r=0.401, p=0.017). A cut-off value was determined as the 95th percentile of the RGE values of 
the healthy volunteers: this value was 0.058 for CD146 and 4.184 for VE-cadherin mRNA. 9 out of 17 patients with 
breast cancer had a RGE of CD146 above the cut-off value; while for VE-cadherin 7 out of 18 patients with breast 
cancer had increased RGEs.
Discussion: Our preliminary results suggest that the quantitative evaluation of endothelial cell-speciﬁ c mRNA by 
real-time RT-PCR technology could indeed be a promising tool to monitor the efﬁ ciency of antiangiogenic therapy 
in patients with breast cancer but a larger study population and a comparison with ﬂ ow cytometry is necessary to 
conﬁ rm this. These studies are ongoing.
Ilse Van der Auwera





THE DIFFERENTIAL EXPRESSION OF GALECTIN-1 AND GALECTIN-3 IN NORMAL LYMPHOID TISSUE AND 
NON-HODGKIN’S AND HODGKIN’S LYMPHOMAS.
Nicky D’Haene, Calliope Maris, Flavienne Sandras, Marie-Françoise Dehou, Myriam 
Remmelink, Christine Decaestecker and Isabelle Salmon.
Laboratory of Pathology, Erasmus University Hospital - Free University of Brussels 
(ULB), Brussels, Belgium.
ABSTRACT :
The WHO classification of lymphomas was established on the basis of clinical, 
morphological, immunohistochemical and genetic criteria. However, each entity 
displays its own spectrum of clinical aggressiveness. Treatment success varies widely 
and is not predictable. Since galectins are involved in oncogenesis and the physiology of 
immune cells, we investigated whether galectin-1 and galectin-3 immunohistochemi-
cal expression could differ in 25 normal lymphoid tissues, 42 non-Hodgkin’s and 14 
Hodgkin’s lymphomas. Immunohistochemical galectin expression was submitted to 
semi-quantitative and quantitative (computer-assisted microscopy) evaluations. This 
study is completed by an analysis (by means of quantitative RT-PCR) of galectin-3 mRNA 
expression in 3 normal lymph nodes, 3 follicular lymphomas (FLs) and 3 diffuse large 
B-cell lymphomas (DLBCLs). The data show that in normal lymphoid tissue, lymphocytes 
do not express galectin-1 and rarely express galectin-3. In contrast, galectin-3 was 
expressed in 8 of the 16 DLBCL cases and in 1 of the 8 FL cases. Furthermore, galectin-
3 mRNA was expressed 3-times more in the DLBCLs than in the FLs. While the blood 
vessel walls of the lymphomas expressed galectin-1, the vessel walls of normal lymphoid 
tissues did not. This expression of galectin-1 in blood vessel walls was correlated with 
vascular density. The present study thus shows that DLBCL can be distinguished from 
normal lymphoid tissue and other lymphomas on the basis of galectin-3 expression. 
In addition, galectin-1 might be involved in lymphoma angiogenesis.
Work published in International Journal of Immunopathology and Pharmacology. 2005; 
18 : 431-443.
Presenting author : D’Haene Nicky - nidhaene@ulb.ac.be
 Laboratoire d’anatomie pathologique
 Hôpital Erasme
 Route de Lennik, 808
 1070 Bruxelles
 02 555 31 15
ROLE OF PKA IN HIF-1α PHOSPHORYLATION IN RESPONSE TO INTERMITTENT HYPOXIA.
S Toffoli†*, O Feron‡, M Raes†, C Michiels†
† Laboratoire de Biochimie et Biologie cellulaire, University of Namur, 61 rue de Bruxelles, B-5000 Namur, 
Belgium.
* E-mail: sebastien.toffoli@fundp.ac.be
‡ University of Louvain Medical School, Unit of Pharmacology and Therapeutics, UCL-FATH 5349, 53 Avenue 
E. Mounier, B-1200 Brussels, Belgium.
It is now well established that vascularized tumors are exposed to intermittent hypoxia, that is, hypoxia 
followed by periods of reoxygenation. Abnormal structure and dysfunction of tumor blood vessels are 
responsible for these conditions. These repeated short periods of hypoxia concern tumor cells as well as 
endothelial cells. However, the effects of intermittent hypoxia on endothelial cells are poorly understood. 
The aim of this study is to investigate the effects of intermittent hypoxia on endothelial cells and particularly 
on HIF-1α, a central actor in adaptive response to hypoxia.
In order to study the effect of intermittent hypoxia, EAhy926 endothelial cells were exposed to repeated 
cycles of hypoxia/reoxygenation. Four repeated cycles of one-hour hypoxia followed by thirty minutes 
reoxygenation were used for a total period of 6 hours.
A modiﬁ cation of HIF-1α phosphorylation pattern under intermittent hypoxia was evidenced. Indeed, in the 
course of hypoxia/reoxygenation cycles, a gradual increase in the abundance of the HIF-1α phosphorylated 
form with respect to its non-phosphorylated form was observed. 
The possible involvement of different kinases, which could phosphorylate HIF-1α under hypoxia, was then 
investigated. The phosphorylation of p42/p44 MAPKs and AKT was followed. An increase in their phosphor-
ylation in the course of hypoxia/reoxygebation cycles was observed and a maximal phosphorylation of p42, 
p44 and AKT was noticed when the abundance of the HIF-1α phosphorylated form was maximal. Treatment 
with PD98059 (a MAPKK inhibitor) or LY294002 (a PI3K inhibitor) induced a decrease in respectively MAPKs 
and AKT phosphorylation. However, no modiﬁ cation in HIF-1α phosphorylation pattern was observed in 
the presence of these inhibitors, indicating that these kinases are problably not involved. 
Other candidates were then investigated: different inhibitors of kinases were used and a modiﬁ cation in 
HIF-1α phosphorylation pattern was observed in the presence of a PKA inhibitor (H-89). An increase in 
the phosphorylation of CREB (a well known PKA substrate) was observed with a maximal phosphoryla-
tion when the abundance of the HIF-1α phosphorylated form was maximal. Incubation in the presence 
of H-89 induced a decrease in the abundance of phopho-CREB but also in the abundance of the HIF-1α 
phosphorylated form.
In conclusion, we showed that repeated cycles of hypoxia/reoxygenation induced a modiﬁ cation in HIF-
1α-phosphorylation pattern in EAhy926 endothelial cells. Activation of p42/p44 MAPKs, AKT and PKA 
was observed in these conditions. The use of inhibitors indicates that PKA seems to be involved in the 
phosphorylation of HIF-1α under intermittent hypoxia, while p42/p44 MAPKs and AKT are not. A better 
knowledge of the effects of intermittent hypoxia on endothelial cells and the highlight of particular 
mechanisms induced by intermittent hypoxia are essential to understand the behaviour of endothelial 
cells during neo-angiogenesis.
Acknowledgments : This work is supported by a Télévie grant
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SPECIFIC ENZYME-MEDIATED ANTICANCER DRUG DELIVERY TO MELANOMA CELLS
Karen Dierickx1, R. Morandini1, G. Ghanem1; L.O.C.E. - Free Univ. of Brussels, Belgium




Most of the conventional anticancer drugs currently in use are based on a differential uptake by 
tumor cells due to their higher metabolism/proliferation. Unfortunately, they also affect normal 
tissues and produce general toxic side effects. Several approaches are being explored to improve 
drug delivery using different systems. This study addresses one of these mechanisms by using tumor 
associated proteases as targets for speciﬁ c drug delivery. We found that some alkylating peptides 
belonging to the old drug Peptichemio are processed efﬁ ciently by tumor proteases. Our present 
work focuses on one of these: PSF (L-prolyl-m-L-sarcolysyl-L-p-ﬂ uorophenylalanine-ethylester) 
in terms of stability, transport, metabolisation and cytotoxic effect. 
While PSF was stable in human plasma, it disappeared very quickly in whole blood along with 
the generation of its main metabolite. The presence of Red Blood Cells (RBC) membranes was 
required for both binding and generation of the metabolites. When RBC ghosts were incubated 
with PSF, a higher generation of m-sarcolysin compared to the incubation of PSF with whole RBC 
was observed. PSF was able to bind the RBC ghosts membranes and could be processed by the 
associated proteolytic enzymes.
Enzymatic catalysis was further supported by a set of experiments where the enzymatic activity 
was inhibited in various ways (e.g. use of protease inhibitors). PSF was exposed to 3 extracellular 
matrix proteases: Collagenase A had no effect, but both Dispase and Trypsine were able to process 
PSF. Melanoma Cells (MC) showed a higher capacity than RBC to bind and process PSF both by 
membrane-associated and soluble proteases. PSF showed the same cytotoxicity proﬁ les towards 
MC with 2 or 48h exposure indicating a rapid uptake. MC were able to completely and rapidly 
generate the active metabolites from RBC-bound PSF. Body distribution of 14C-labeled PSF in 
human melanoma bearing nude mice showed a signiﬁ cant increase of accumulation only in the 
tumor tissue. A dose ﬁ nding study in nude mice allowed us to administer up to 20 mg/kg IP single 
dose that was able to induce, unlike an equivalent dose of melphalan or m-SL, not only inhibition 
of growth but also tumor regression without any signiﬁ cant weight loss. Dose-response curves 
where achieved and fractionated doses had signiﬁ cant better effects on tumor regression and 
regrowth than a single dose.
Our results strongly suggest a particular delivery system based on a rapid binding to BC, subsequent 
transport, followed by a proteolytic activation at the targeted tumor sites, drug targeting being 
achieved by the much higher load in proteolytic enzymes in tumors. Drug delivery is accomplished 
through an active competition between BC-membrane bound enzymes and, soluble as well as 
tumor-membrane-associated peptidases.
THE RADIOSENSITIZING EFFECT OF GEMCITABINE AND APOPTOSIS: EXTRINSIC OR INTRINSIC ACTIVATION?
Bea Pauwels, Veronique Huygelen, Greet G.O. Pattyn, Hilde A.J. Lambrechts, Dirk R. Van Bockstaele, 
Katrien Vermeulen, Marc Lenjou, Jan B. Vermorken & Filip Lardon
Laboratory for Cancer Research and Clinical Oncology University of Antwerp.
Both in clinical and preclinical studies it is shown that gemcitabine has clear radiosensitizing 
properties. This radiosensitizing effect is dependent of the cell cycle effect, an early S phase block 
followed by a G
2
/M block, and an increased induction of apoptosis. This study was performed to 
clarify the apoptotic pathway responsible for radiosensitization by gemcitabine. We investigated 
the activation of caspase 8 and 9, both initiator caspases of the extrinsic or intrinsic pathway, 
respectively.
The cell lines used for this study were ECV304 (mt-p53), a human bladder cancer cell line and H292 
(wt-p53), a human mucoepidermoid lung cancer cell line. The cells were treated with gemcitabine 
(IC25 and IC90) during 24 h, radiotherapy (γ-Co60, 0-6 Gy, room temperature), or with the combina-
tion, i.e. gemcitabine immediately followed by radiation. 72h after treatment, apoptotic cell death 
is determined using TUNEL assay, Annexin V staining and caspase 3 activity assay. Caspase 8 and 
9 activation is determined by Western blot at different time points (0-72h) after gemcitabine or 
radiotherapy and 72 h after the combination. Using the mitochondria-selective probe (tetrameth-
ylrhodamine methylester) and ﬂ ow cytometry, the mitochondrial membrane potential (ψ) was 
determined. 
72 h after treatment, the combination of gemcitabine and radiotherapy resulted in a clear increase 
of apoptosis in both cell lines. At that moment, both procaspase 8 and 9 cleaving was observed with 
Western blot. In addition, ψ was reduced when the amount of annexin V positive cells increases. 
To determine the order of caspase 8 and 9 activation, caspase cleaving was determined at different 
time points after gemcitabine or radiotherapy. In both settings, caspase 8 activation was observed 
at the different time points after treatment, while no cleaving products of caspase 9 could be 
shown. 
In conclusion, treatment of ECV304 and H292 cells under radiosensitizing conditions resulted in an 
increased induction of apoptosis with caspase 8 and 9 cleaving and a reduction of ψ. This means that 
both the extrinsic and the intrinsic pathway is activated. However, treatment with gemcitabine or 
radiotherapy alone resulted only in activation of the extrinsic pathway. Further research is necessary 
to investigate the caspase 9 activation under radiosensitizing conditions. This could be a result of 
the increased apoptosis by the combination of gemcitabine and radiation or by Bid activation, the 
link between the intrinsic and the extrinsic pathway.
This work is supported by a grant of the Belgian Federation against cancer.
COMBINED PAP AND HPV TESTING IN PRIMARY SCREENING FOR CERVICAL ABNORMALITIES: SHOULD HPV 
DETECTION BE DELAYED UNTIL AGE 35?
Marc F.D. Baay1, Wiebren A.A. Tjalma2, Hilde A.J. Lambrechts1, Greet G.O. Pattyn1, Filip 
Lardon1, Joost Weyler3, Paul Van Royen4, Eric A.E. Van Marck5 and Jan B. Vermorken1
1 Dept. Medical Oncology, 2 Dept. Gynaecology and Gynaecological Oncology, 3 Dept. 
Epidemiology and Community Medicine, 4 Centre for General Practice, 5 Dept. Pathology, 
University of Antwerp (UA/UZA), Antwerp, Belgium. Marc.Baay@ua.ac.be
Background: In 2003, the United States Food and Drug Administration has approved 
the Hybrid Capture 2 assay for use with a Pap test to adjunctively screen women of 
30 years and older for the presence of high-risk HPV infection. Although the predictive 
power of a negative test is strong, the number of false-positives may still be high. We 
investigated HPV prevalence in relation to age in a group of 2,293 women, aged between 
20 and 50, with normal cytology. 
Methods: Residual material from thin-layer cytology was used for DNA isolation. DNA 
integrity was checked by beta-globin PCR and HPV DNA was detected by the GP5+/6+ 
general primer PCR, followed by non-radioactive enzyme immunoassay detection. Probes 
for 14 high-risk types were available. 
Results and discussion: Overall HR-HPV prevalence was 6.9% (95%CI = 5.9 – 8.0%). The 
age-related HR-HPV prevalence was analysed in 10-year intervals, in 5-year intervals 
and in intervals of 1 year. Using 1-year intervals, peaks were found at the ages 22, 23 
(11.6 and 12.5%, respectively) and at the ages 31, 32 (12.4 and 11.6%, respectively). 
Using 5-year intervals the HPV prevalence remained stable at approximately 9% in 
the age groups 20-24, 25-29 and 30-34, and decreased signiﬁ cantly to approximately 
5% in the age groups 35-39, 40-44 and 45-50. This would suggest that postponing 
HPV detection in primary screening from age 30 to age 35 would result in a decrease 
of almost 50% of the number of women with normal cytology and a transient HPV 
infection, potentially saving thousands of women in North-Western Europe from 
being diagnosed with a wide-spread sexually transmitted infection. Investigation of 
the emotional and psychosocial impact of being diagnosed with HPV showed that 
women commonly experienced emotional distress (anger, anxiety, depression, fear 
of rejection, shame and guilt), sexual problems and a negative self-image. Careful 
consideration has to be taken whether the positive side of HPV detection (detection 
of women with high-grade lesions, missed by cytology) outweighs the negative side 
(distress in HPV positive women without cervical lesions). Our data suggest that these 
opposites are more balanced at a higher age.
SCHEDULE DEPENDENCY OF THE RADIOSENSITISING EFFECT OF VINFLUNINE AND THE ROLE OF ITS CELL CYCLE EFFECTS, IN VITRO. 
Cindy Simoens1, Filip Lardon1, Bea Pauwels1, Christel M.J. De Pooter2, Fabienne Breillout3 & Jan B. Vermorken1
1Dept. Of Medical Oncology, University of Antwerp, Wilrijk, Belgium
2St. Augustinus hospital, Antwerp, Belgium
3Institut de Recherche Pierre Fabre, Boulogne, France
Tel.: +32 3 820 25 76, Fax: +32 3 820 22 48, E-mail: Cindy.Simoens@ua.ac.be
Vinﬂ unine proved to have radiosensitising potential and caused a clear G2/M blockade (Simoens et al., CCP, in 
press). However, further investigation was necessary to elucidate the exact role of this cell cycle effect. The purpose 
of this study was to correlate the cell cycle effects of vinﬂ unine with the radiosensitising effect using different 
treatment schedules.
ECV304, a human bladder cancer, and CAL-27, a human head and neck cancer cell line were treated with radiosensitis-
ing vinﬂ unine-concentrations (50nM and 20nM, respectively). To investigate the inﬂ uence of the incubation time, 
cells were treated during 8, 24 or 48hrs prior to radiation (Co-60γ rays, 0-8 Gy, room temperature). The inﬂ uence of 
a time interval was tested by 24h incubation with vinﬂ unine, 0, 8 or 24hrs before irradiation (24+0, 24+8, 24+24). 
Cell survival was determined by the sulforhodamine B assay 7 or 8 days after radiation and radiosensitisation was 
represented by the Dose Enhancement Factor (DEF). To determine the role of the cell cycle perturbations caused by 
vinﬂ unine at the moment of radiation, cells were analysed by ﬂ ow cytometry (DNA staining). Cells were treated with 
150nM (ECV304) and 100nM vinﬂ unine (CAL-27) using the above mentioned treatment schedules.
In both ECV304 and CAL-27, 8h of incubation did not resulted in a radiosensitising effect, although a signiﬁ cant 
increase in G2/M phase cells was observed. This increase was probably not strong enough to compensate for the 
simultaneous signiﬁ cant increase in S phase cells (most radioresistant) at that time. Maximum radiosensitisation 
was reached after 24h incubation (maximum G2/M block) and decreased with longer incubation times (48h), due 
to a decrease of G2/M phase cells and an increased polyploid population.
Using different time intervals, maximum radiosensitisation (DEF=2,01) was observed after 24h incubation 
immediately followed by radiation (24+0) in ECV304. This also resulted in the largest arrest at G2/M (57,3% 
versus 17,8% in control cells). Radiosensitisation gradually decreased with an increasing time interval between 
vinﬂ unine-treatment and radiation, due to a decrease in G2/M, an increase in G1 (24+8) and an increase in the 
polyploid population (24+24). In CAL-27, radiosensitisation was most pronounced after an 8h interval between 
vinﬂ unine-treatment and radiation (24+8) (DEF=2,36 versus 1,79 immediately after the 24h incubation period (24+0)). 
The only linked cell cycle effect was the lowest amount of S phase cells at that time, although the amount of G2/M 
cells was already signiﬁ cantly decreased compared to 24+0. A 24h interval (24+24) resulted in a strong decrease of 
radiosensitisation, together with the highest amount of cells in S and the polyploid population.
In conclusion, the radiosensitising effect of vinﬂ unine after different treatment schedules is cell line-dependent. 
The observed G2/M block cannot explain the altered radiosensitivity all by itself. Other cell cycle effects, like 
the presence of S phase and polyploid cells, also play an important role in the radiosensitivity after vinﬂ unine-
treatment. Possibly, other non-cell cycle-related causes may exist.
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IN VITRO CYTOTOXIC ACTIVITY OF PEMETREXED ALONE AND IN COMBINATION WITH IRRADIATION.
An Wouters, Cindy Simoens, Bea Pauwels, Greet G.O. Pattyn, Hilde A.J. Lambrechts, Christel M.J. De Pooter, 
Filip Lardon and Jan B. Vermorken
Dept. of Medical Oncology, University of Antwerp, Wilrijk, Belgium 
Tel: +32 3 820.25.75, Fax: +32 3 820.22.48, Email: an.wouters@ua.ac.be
Introduction: Pemetrexed (Alimta, LY231514, Eli Lilly and Co.) is a novel generation antifolate that targets 
multiple folate-dependent enzymes involved in purine and pyrimidine synthesis. It has been shown that 
pemetrexed exhibits antitumour activity against a broad spectrum of human malignancies, including 
pancreatic, lung, mesothelioma, head and neck and cervical cancers. Since these tumour types are often 
treated using chemotherapy in combination with radiotherapy, pemetrexed might be an interesting 
cytostatic agent to incorporate in chemoradiation protocols. Indeed, previous in vitro studies suggest a 
moderate radiosensitising effect of pemetrexed.
This study focuses on the in vitro cytotoxic activity of pemetrexed in 3 human tumour cell lines. Moreover, 
the interaction between pemetrexed and irradiation is investigated using different treatment schedules.
Materials & methods: The human tumour cell lines examined are CAL-27 (a squamous cell carcinoma cell 
line of the tongue), A549 (a lung carcinoma cell line) and PANC-1 (an epitheloid carcinoma cell line of 
the pancreas). For the cytotoxicity experiments, cells were incubated with pemetrexed (0 – 1500 µM) for 
24h. In combination with radiotherapy, cells were treated with pemetrexed for 24 h immediately before or 
after radiation (γ-Co60, 0 – 8 Gy, room temperature). Cell survival was determined by the sulforhodamine B 
assay. For the cytotoxicity assays, the concentration pemetrexed resulting in 50 % growth inhibition (IC
50
) 
was calculated. Dose survival curves for the combination studies with radiation were ﬁ tted according to 
the linear-quadratic model and the ID
50
 represented the radiation dose producing 50 % growth inhibition. 






Results: For CAL-27 and A549 cells, the IC
50
 for pemetrexed was situated in the nanomolar range (123.7 ± 
19.3 nM and 639.9 ± 68.8 nM respectively). In PANC-1 cells however, the cytotoxic effect of pemetrexed was 
much less pronounced and concentrations as high as 1500 µM resulted in only 30 % growth inhibition.
In combination with radiotherapy, pemetrexed exposure (concentrations ≤ IC
60
) 24 h before irradiation 
was unable to mediate a clear radiosensitising effect in CAL-27 and A549 cells. For both cell lines, the DEF 
was about 1.00 for different concentrations pemetrexed, indicating only additive toxicities. In CAL-27 
cells, the inverse schedule (i.e. irradiation followed by treatment with pemetrexed) could not establish 
radiosensitisation either.
Conclusion: The in vitro cytotoxic activity of the novel folate antimetabolite pemetrexed is clearly 
concentration and cell line dependent. In combination with radiation, no radiosensitising effect could be 
demonstrated so far, but further experiments are necessary.
IN VITRO INTERACTION BETWEEN PEMETREXED AND GEMCITABINE USING DIFFERENT TREATMENT SCHEDULES.
An Wouters, Bea Pauwels, Cindy Simoens, Hilde A.J. Lambrechts, Greet G.O. Pattyn, Filip 
Lardon and Jan B. Vermorken
Dept. of Medical Oncology, University of Antwerp, Wilrijk, Belgium 
Tel: +32 3 820.25.75, Fax: +32 3 820.22.48, Email: an.wouters@ua.ac.be
Introduction: Pemetrexed (Alimta, LY231514, Eli Lilly and Co.) is a novel antimetabolite that 
targets multiple folate-dependent enzymes involved in purine and pyrimidine synthesis. 
Pemetrexed and gemcitabine (a deoxycytidine analogue) both have shown preclinical and 
clinical activity against a broad spectrum of tumour types. Based on their different mechanisms 
of action and their non-overlapping toxic side effects, the combination of these two antimetab-
olites seems promising. The present study investigates the interaction between pemetrexed 
and gemcitabine using different treatment schedules in 2 human tumour cell lines.
Materials & methods: The human tumour cell lines examined are CAL-27 (a squamous cell 
carcinoma cell line of the tongue) and A549 (a lung carcinoma cell line). Cells were treated 
with pemetrexed alone (0 – 2000 nM), gemcitabine alone (0 – 100 nM) or with a combination 
of both chemotherapeutics where one drug was added at a ﬁ xed concentration, while the 
other drug was added in a concentration range. Three different combination regimens were 
tested: (1) simultaneous exposure to pemetrexed and gemcitabine for 24 h; (2) gemcitabine 
treatment for 24 h immediately followed by pemetrexed for 24 h and (3) the reverse sequence, 
i.e. pemetrexed for 24 h immediately followed by exposure to gemcitabine for 24 h. Cell 
survival was determined by the sulforhodamine B assay and drug interaction was evaluated 
by median drug analysis by calculating the combination index (CI).
Results: A simultaneous treatment using a concentration range of pemetrexed and a ﬁ xed, 
non-toxic concentration of gemcitabine or vice versa, resulted in CAL-27 cells in an additive 
to synergistic effect with low concentrations and in an antagonistic effect using higher 
concentrations. Both schedules resulted in antagonism in A549 cells.
When the cells were treated during 24 h with pemetrexed immediately followed by a 24 
h incubation with gemcitabine, using a concentration range or a ﬁ xed dose, an additive to 
synergistic effect is observed in CAL-27 cells in the lower concentration range, while moderate 
antagonism is observed at higher concentrations. In A549, this schedule resulted only in an 
antagonistic to additive effect. When 24 h gemcitabine treatment is followed by pemetrexed 
for 24 h, the same trend is observed in CAL-27 and A549 cells as the previous schedule.
Conclusion: So far, it is difﬁ cult to determine the optimal combination regimen of pemetrexed 
and gemcitabine. Therefore, a third cell line and additional treatment schedules will be investi-
gated. At present, our experiments indicate that the in vitro interaction between pemetrexed 
and gemcitabine is clearly dependent on the cell line, the concentration of the drugs and the 
treatment regimen used.
PROGNOSTIC SIGNIFICANCE OF MICROSATELLITE INSTABILITY IN A BELGIAN COLORECTAL CANCER STUDY POPULATION.
V. Deschoolmeester1, N. Van Damme2, M. Baay1, K. Claes3, E. Van Marck4, W. Wuyts5, J. Weyler6, F. Lardon1, J.B. Vermorken1 and M. 
Peeters2 
1Department of Medical Oncology, 4Department of Pathology 5Department of Medical Genetics, 6Department of Epidemiology and 
Community Medicine, University of Antwerp (UA/UZA),Wilrijk, Belgium
2Department of Gastroenterology, 3Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium
The development of colorectal cancer (CRC) is heterogeneous involving several genetic pathways, including chromosomal instability 
and microsatellite instability (MSI). 
In accordance with the strong need for more targeted adjuvant therapy in early stage CRC patients, discriminating prognostic markers 
for outcome are required. 
Although no consensus has been reached, MSI appears to be a promising marker since growing evidence shows differences in outcome, 
survival and prognosis in MSI- and microsatellite stable (MSS) patients.
To determine the use of MSI as prognostic marker, several clinical and histopathological features as well as the MSI status were evaluated 
in 199 CRC samples obtained from 189 patients treated at the University Hospital of Antwerp (UA) (123), at Ghent University Hospital 
(UG) (42), at the Heilig Hart Hospital in Roeselare (24) and at AZ St.-Jan in Bruges (10) to date.
Formalin-ﬁ xed, parafﬁ n-embedded blocks were subjected to microdissection in UA while in UG (76), normal tissue was derived from 
matched peripheral blood leukocytes. The polymerase chain reaction (PCR) was used for MSI-analysis. In addition to the Bethesda 
reference panel, 5 additional 18S markers were examined in UG. If the Bethesda markers showed a low level of MSI (MSI-L) or less than 
5 markers were ampliﬁ able, 5 additional markers were analyzed in UA. The result obtained by UA and UG were in good agreement. A 
high level of MSI (MSI-H) was deﬁ ned as having instability in 30-40% or more markers, MSI-L was deﬁ ned as having instability in less 
than 30-40% of the markers, whereas in MSS no apparent instability was noted.
Preliminary results indicate that of the samples analyzed to date, 6.5% showed MSI-H, 4% showed MSI-L and 89.5% was MSS. The 
study comprised 80 females and 109 males. There seems to be a trend towards proximal location (p= 0.06, Fisher’s Exact Test) in MSI-H 
tumors compared to MSI-L/MSS. No major difference is noted in age, sex, tumor stage and differentiation grade (Table).
MSI-H % MSI-L % MSS % MSI-H % MSI-L % MSS %
Age 60.1 51.5 56.8 TNM
range 36-73 36-71 29-88 T0 0/12 0 0/13 0.0 1/168 0.6
sex T1 0/12 0.0 0/13 0.0 5/168 3.0
men 7/13 53.8 7/14 50 69/167 41.3 T2 2/12 16.7 1/13 7.7 25/168 14.9
women 6/13 46.2 7/14 50 98/167 58.7 T3 8/12 66.7 6/13 46.2 96/168 57.1
differentiation T4 2/12 16.7 2/13 15.4 22/168 13.1
grade bad 2/11 18.1 0/12 0.0 8/143 5.6 Tx 0/12 0.0 4/13 30.8 18/168 10.7
bad-medium 1/11 9.1 0/12 0.0 6/143 4.2 Tis 0/12 0.0 0/13 0.0 1/168 0.6
medium 5/11 45.5 8/12 66.7 85/143 59.4
medium-well 0/11 0.0 1/12 8.3 12/143 8.4 N0 6/12 50.0 4/13 30.8 78/168 46.4
well 3/11 27.3 3/12 25.0 32/143 22.4 N1 2/12 16.7 6/13 46.2 50/168 29.8
tumor N2 3/12 25.0 2/13 15.4 29/168 17.3
location proximal 8/12 66.7 5/13 38.5 58/166 34.9 Nx 1/12 8.3 1/13 7.7 11/168 6.5
distal 4/12 33.3 8/13 61.5 108/166 65.1
adjuvant M0 4/12 33.3 2/12 16.7 39/169 23.1
therapy no 5/7 71.4 3/11 27.3 20/104 19.2 M1 3/12 25.0 5/12 41.7 43/169 25.4
chemo 1/7 14.3 6/11 54.5 65/104 62.5 Mx 5/12 41.7 5/12 41.7 87/169 51.5
RT 1/7 14.3 1/11 9.1 2/104 1.9
chemo + RT 0/7 0.0 1/11 9.1 17/104 16.3
Currently full statistical analysis is being performed. Our data and correlations may help to further elucidate the use of MSI analysis 
as a prognostic factor in sporadic colorectal cancer.
REGULATION OF THE TRANSCRIPTIONAL ACTIVITY OF HUMAN PAPILLOMAVIRUS TYPE 16 LCR IN CHORIOCARCINOMA 
CELL LINES.
Weyn Christine*, Jazouli Nawal, Bernis Aurore and Fontaine Véronique.
Laboratory of Molecular Virology, Pasteur Institute, 642, rue Engeland, 1180 Bruxelles, Belgium. 
*presenting author: christineweyn@yahoo.com
Over 100 types of human papillomavirus (HPV) have been identiﬁ ed to date. They all are 
small circular DNA viruses that infect epithelial cells from various mucosal and cutaneous 
sites but have strong tissue and species tropism. Because of their association with malignancy, 
especially cervical cancer, certain HPV types that infect the anogenital mucosa are of particular 
concern. About 15 types (such as HPV 16 and 18) are termed high risk and are associated 
with more than 99% of the cervical carcinoma. On the opposite, low risk HPV are only rarely 
associated with malignancy. 
Genital HPV have also been reported in association with spontaneous abortions and develop-
ment of precancerous (molar pregnancy) or cancerous gestational trophoblastic diseases 
(choriocarcinoma). Several studies report that HPV could infect trophoblasts during pregnan-
cies. The trophoblast is an embryonic epithelial cell, which plays an essential role in various 
biological processes such as anchoring, materno-foetal exchanges, immune tolerance and 
endocrine regulation of the development of the pregnancy. It secretes many hormones such as 
the hCG (human chorionic gonadotropin) and many cytokines (IL-1, IL-6, IL-8, IL-10, LIF, TNFa, 
M-CSF, EGF and IFN). Surprisingly HPV can replicate in vitro in human trophoblasts. 
The early proteins (E) from high risk HPV play a pivotal role in tumor development and have 
been also reported to disturb some activities involved in the trophoblast differentiation. The 
transcription of the early region of HPV 16 is initiated at the p97 promoter and is regulated 
by the long control region (LCR). Both viral (E2) and various cellular transcription factors, 
including AP-1, C/EBPb, nuclear factor 1 (NF-1), c-myb, Sp1, TEF-1, PEF-1, Oct-1, NF-kB and 
YY-, have been reported to either activate or inhibit the HPV 16 LCR. 
To study the regulation of the HPV16 LCR in four choriocarcinoma cell lines, we transfected 
all the cell lines with the pWtLCR-Luc plasmid and analysed the luciferase activity expressed 
under the control of the HPV16 LCR. This activity was relatively high in three cell lines, even 
higher than in the cervical carcinoma Siha cell line for one of them. Surprisingly, in a fourth 
choriocarcinoma cell line, the luciferase activity was considerably reduced. It seems that 
cellular factors secreted by these cell lines could play an important role in the activation or 
inhibition of the LCR. Although dexamethasone is also a strong activator of the transcriptional 
activity of the HPV 16 LCR in all choriocarcinoma cell lines, it doesn’t seem that endogenous 
progesterone plays a similar role. The involvement of various transcriptional factors for the 
HPV16 LCR activity in these trophoblastic cell lines is currently under investigation.
94
Acta Clinica Belgica, 2006; 61-2
ABSTRACTS OF THE MEETING OF THE BELGIAN ASSOCIATION FOR CANCER RESEARCH
27 28
29 30
MEMBRANE-TYPE 4-MATRIX METALLOPROTEINASE PROMOTES BREAST CANCER GROWTH AND METASTAS-
ES.
Chabottaux V.1, Sounni N.E.1, English W.R.2, van den Brûle F.1, 3, Gilles C.1, Munaut C.1, 
Maquoi E1, Lopez-Otin C.4, Murphy G.2, Foidart J.M.1, 3 and Noël A.1
1 Laboratory of Tumor and Development Biology, University of Liège, Sart Tilman 
B23, Center for Experimental Cancer Research (CECR), Center for Biomedical Integra-
tive Genoproteomics (CBIG), B-4000 Liège, Belgium; 2 Department of Oncology, 
Cambridge Institute for Medical Research, Cambridge University, Cambridge CB2 2XY, 
UK; 3 Department of Gynecology, CHU, B-4000 Liège; 4 Departamento de Bioquímica 
y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, 
Universidad de Oviedo, 33006-Oviedo, Spain.
Membrane-type matrix metalloproteinases (MT-MMPs) constitute a subfamily of 6 
distinct membrane-associated MMPs. Although the contribution of MT1-MMP during 
different steps of cancer progression has been well documented, the signiﬁ cance of 
other MT-MMPs is rather unknown. We have investigated the involvement of MT4-MMP, 
a glycosylphosphatidyl-inositol (GPI) anchored protease in breast cancer progression. 
RT-PCR analysis reveals MT4-MMP expression in human breast adenocarcinomas 
tissues. Interestingly, MT4-MMP protein is strongly detected by immunohistochemis-
try in epithelial cancer cells of all human breast carcinomas tested and in lymph node 
metastasis. Stable transfection of MT4-MMP cDNA in human breast adenocarcinoma 
MDA-MB-231 cells does not affect in vitro cell proliferation or invasion, but strongly 
promotes primary tumor growth and metastatic dissemination in RAG-1 immunode-
ﬁ cient mice. We provide for the ﬁ rst time evidence that MT4-MMP over-production 
accelerates in vivo tumor growth, induces enlargement of blood vessels and increases 
lung metastasis. These results identify MT4-MMP as a new putative target to design 
anti-cancer strategies.
HPV TYPE 16 E7 MRNA ELECTROPORATED DENDRITIC CELLS AS A POSSIBLE MODALITY FOR THERAPEUTIC 
TUMOR VACCINATION.
Nathalie Cools, Peter Ponsaerts, Marc Lenjou, Griet Nijs, Dirk Van Bockstaele, Zwi 
Berneman, Viggo Van Tendeloo.
University of Antwerp, Faculty of Medicine, Laboratory of Experimental Hematology, 
Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium.
Human Papillomavirus (HPV) infection is the primary risk factor for cervical cancer, 
the second most common gynecological cancer among women worldwide. Despite 
optimized protocols, standard treatments still face several disadvantages. Therefore, 
novel research aims at the development of immune-based therapies such as loading 
dendritic cells (DC) with tumor antigens for the induction of anti-tumor immunity.
For this purpose, we – initially - used an HLA-A2-restricted HPV-16 E7
11-20
 peptide for 
the loading of DC in order to induce a T cell response in vitro. Peptide-pulsed DC were 
brought into coculture with autologous CD8+ T cells. Following 4 weekly restimula-
tions with peptide-pulsed DC, cultured T cells were subsequently analyzed for antigen 
speciﬁ city by ELISPOT after restimulation with target cells or control cells. With the 
ELISPOT assay, we detected E7-speciﬁ c IFN-gamma secretion by CD8+ T cells in 5/5 
healthy donors.
There are however some limitations linked to the use of peptides. Peptide-pulsed 
dendritic cells only express one tumor associated epitope and this in an HLA restricted 
manner. To overcome these limitations, we explore HPV type 16 E7 mRNA electro-
poration in dendritic cells in an immune activating setting. We are able to detect the 
electroporated mRNA by means of RT-PCR several days after electroporation. Moreover, 
these HPV type 16 E7 mRNA electroporated dendritic cells are capable of stimulating 
antigen-speciﬁ c IFN-γ production by a HPV type 16 E7 speciﬁ c cytotoxic T cell clone.
In conclusion, we showed that dendritic cells, antigen-loaded by different means, are 
able to stimulate a HPV type 16 speciﬁ c immune response. These experiments concern 
the development of cultivation protocols for cytotoxic T cells in preclinical vaccination 
strategies. In future studies we will investigate if mRNA-electroporation will contribute 
to the generation of a more efﬁ cient immune response.
THINK TWICE BEFORE YOU SPLICE: CONSTITUTIVE P120CTN EXON C EXPRESSION/DEPLETION AFFECTS 
NORMAL MOUSE EMBRYOGENESIS.
Tim PIETERS, Petra D’ HOOGE, Frans VAN ROY and Jolanda VAN HENGEL 
Molecular Cell Biology Unit, Department for Molecular Biomedical Research, Flanders 
Interuniversity Institute for Biotechnology (VIB) and Ghent University, Technologiepark 
927, B-9052 Ghent (Zwijnaarde), Belgium. Tim.Pieters@dmbr.UGent.be
p120 catenin (p120ctn) belongs to the Armadillo family and is the only catenin that 
is not directly involved in linking cadherins to the actin cytoskeleton. Instead, p120ctn 
fulﬁ ls pleiotropic functions according to its subcellular localisation: (i) modulating the 
turnover rate of membrane-bound cadherins, (ii) regulating the activation of small Rho 
GTPases in the cytoplasm and (iii) modulating nuclear transcription. This multifunc-
tionality can be explained by the presence of 48 possible human p120ctn isoforms 
originating from 4 start codons and 4 alternatively used exons. The alternatively used 
exon C encodes 6 amino acids that interrupt a nuclear localisation sequence (NLS) in 
the large insert loop between arm repeats 5 en 6 of the central armadillo domain. This 
disruption abrogates the inhibition of RhoA. In fact, both the subcellular localisation 
and the mode of action of p120ctn can be regulated directly by alternative splicing, 
hence the need for more detailed research on the p120ctn isoforms.
To assess the in vivo function of exon C we generated p120ctn exon C-speciﬁ c knock-
out (KO-C) and knock-in (KI-C) mice. Offspring derived from crossing heterozygous 
KO-C mice gave rise only to heterozygous KO-C and wild-type mice in a 2:1 ratio, 
indicating prenatal mortality. To identify the embryonic stage at which mortality 
occurs in homozygous KO-C mice, embryos between 7.5 and 16.5 dpc were isolated 
and genotyped; they too displayed a 2:1 ratio. Paraformaldehyde-ﬁ xed parafﬁ n sections 
of gastrulating embryos (6.0-8.5 dpc) were morphologically staged but no reproduc-
ible aberrations could be detected. Remarkably, the constitutive expression of exon C 
also causes prenatal mortality of homozygous KI-C mice amongst the neonates and 
8.5 to 16.5 dpc embryos derived from heterozygous KI-C crosses. Currently we are 
investigating preimplantation and early-postimplantation stages for KO-C and KI-C 
mice to provide molecular insight into how disregulated splicing of the smallest exon 
in the p120ctn gene can have a tremendous effect on the development and viability 
of an entire organism.
NUCLEAR GALECTIN-3 EXPRESSION IS AN INDEPENDENT PREDICTIVE FACTOR OF RECURRENCE FOR ADENOCARCINOMA 
AND SQUAMOUS CELL CARCINOMA OF THE LUNG
Anne Mathieu, Isabelle Saal, Hans-Joachim Gabius, Robert Kiss, Christine Decaestecker, Isabelle 
Salmon and Myriam Remmelink.
ULB Erasme
Hypothesis/background: The tumor stage is the most powerful prognostic tool for predict-
ing the survival rates of lung carcinoma patients. However, prognosis of individual patients is 
difﬁ cult in part because of the marked clinical heterogeneity among such patients. Galectin-
sare involved in cell growth, apoptosis and cell migration features, and their diagnostic and 
prognostic values have already been demonstrated in various types of cancers. In the present 
paper we analyze the potential prognostic value of immunohistochemical galectin-3 expression 
in lung adenocarcinomas and squamous cell carcinomas.
Methods: 165 squamous cell carcinomas and 121 adenocarcinomas were immunostained 
for galectin-3. In each case the immunohistochemical analyses consisted of an evaluation of 
the percentage of tumor cells stained and the intensity of staining. An IP score (i.e. Intensity 
x Percentages) was thus determined for each lung carcinoma.
Results: A large majority of cases displayed galectin-3 expression. While the cytoplasmic 
staining in the squamous cell carcinomas was focal and moderately intense, the staining in 
the adenocarcinomas was diffuse and intense. The IP scores were signiﬁ cantly (p = 0.0001) 
higher in the adenocarcinomas than in the squamous cell carcinomas. The difference in nuclear 
expression proﬁ les between the two cancer types was statistically signiﬁ cant (p = 0.0005). 
Cox multivariate analysis carried out on the patients’ genders, the TNM classiﬁ cation and the 
galectin-3-related variables showed that of the galectin-3-related variables, only the nuclear 
location of galectin-3 was identiﬁ ed as a prognostic indicator of recurrence independent of the 
clinicopathological features characterizing the patients (p = 0.02). The prognostic contribution 
of this latter variable was enhanced when the patients with relapse-free follow-ups longer 
than 8 months were considered (p = 0.005).
Conclusions: Galectin-3 immunohistochemical expression differs between squamous cell 
carcinomas and adenocarcinomas, but the nuclear expression of galectin-3 behaves as a 
signiﬁ cant prognostic predictor for all the cases as a group.
Presenting authors : 
Myriam Remmelink Anne Mathieu
Hopital Erasme Hopital Erasme
808 route de Lennik 808 route de Lennik
1070 Bruxelles 1070 Bruxelles
Tel :02/555.31.15 Tel :02/555.31.15
Email : mremmeli@ulb.ac.be Email : anmathie@ulb.ac.be
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IDENTIFICATION OF AP-2 COFACTORS IN BREAST CANCERS OVEREXPRESSING ERBB2.
Nolens Grégory
Oncologie Moléculaire (Ulg), Laboratoire de Spectrométrie de Masse (Ulg), Centre de 
Recherche sur les Protéines Prion (Ulg).
Contact: Nolens Grégory - gnolens@ulg.ac.be - Tel: 0032477443481
Introduction
In breast cancer cells, the promoter activity of the oncogene ERBB2 is controlled by 
transcription factors of AP-2 family, which ﬁ x sequences in the promoter region. Like 
all transcription factors, the AP-2 factors modulate the transcription by interacting 
with many proteins (cofactors). Contrary to others cellular types, high concentrations 
of AP-2 factors are transcriptionaly active in breast cancers overexpressing ERBB2. Our 
assumption is that this characteristic is due to the presence of speciﬁ c cofactors in breast 
cancer for AP-2 to remain active. Our goal is to identify these cofactors interacting with 
AP-2 in breast cancer cells. The techniques undertaken were the afﬁ nity chromatography 
on DNA (ACD) and the technique of GST-pull-down (GPD). 
Description of the techniques 
These techniques would allow identifying proteins interacting with AP-2. The ACD 
technique uses speciﬁ c sequences of DNA including a biotin on 5’ end. This biotin 
allows ﬁ xing on streptavidin covering magnetic beads. The GPD uses proteins coupled 
with the GST (Glutathion Serine Transferase), called chimera proteins (here GST-AP2). 
This one has an afﬁ nity for the glutathion covering magnetic beads. Nuclear proteins 
extracts from AP-2 overexpressing cells are incubated with these beads then, after 
washing, the proteins interacting with the DNA or the chimera protein is eluted. After 
separation of these last on 2 dimensions gel of electrophoresis, the interesting proteins 
are digested and their peptides separated and analyzed by liquid chromatography 
coupled with tandem mass spectrometry (LC-MS/MS). 
Results 
These techniques require many optimizations and have disadvantages differing one 
from the other. AP-2 α and γ were succefully isolated by the DNA afﬁ nity technique 
and identiﬁ ed by mass spectrometry. The following step was the identiﬁ cation of the 
interacting proteins. Recently, several proteins were isolated like interacting with AP-2. 
Their identiﬁ cations are in progress. When those will be made, the interactions will be 
conﬁ rmed by other techniques and the effect of these proteins on the transcriptional 
role of AP-2 will be studied by report vectors like by studies of interference with the 
RNA (siRNA).
HPV AND THE DUCTUS DEFERENS
N. Toussaint5, S. van de Calseijde5, C.E. Depuydt2, A.J. Vereecken2, M. Stalpaert2, J. Bogers2, 3, K. D’Hauwers1, W. 
Tjalma4
Departments of 1Urology, 3Pathology and 4Gynecology, University Hospital Antwerp, University Antwerp, B-2650 
Antwerp, Belgium and the 2Labo Riatol, Laboratory for Clinical Pathology, B-2000 Antwerp, Belgium. Graduate 
Students Medicine5, University Antwerp, B-2650 Antwerp, Belgium.
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Abstract
Aim : Human papillomavirus infection (HPV) is causally associated with uro-genital (pre) malignant lesions and 
carcinomas. It is considered to be a sexual transmitted disease. Although knowledge of HPV infection in women 
is extensive, limited information is available about the prevalence and behaviour of HPV in men. The role of the 
male reproductive tract as harbouring reservoir for HPV is poorly understood. The aim of the current study is to 
investigate the presence of HPV in the vas deferens in a male standard population. 
Methods : 30 healthy male patients who had a classic bilateral vasectomy in the University Hospital in Antwerp 
(UZA) between 1999 and 2004 were included. With the incidence of HPV infection in women in mind, we selected 
two groups of ﬁ fteen men, respectively aged 35 years and younger (group 1) and 45 years and older (group 2). 
From sections of stored parafﬁ n embedded tissue samples of the vas deferens obtained after the vasectomies, 
genomic DNA was extracted using the QIAamp DNA mini kit®. HPV DNA detection was performed using real-
time polymerase chain reaction (PCR) for 15 oncogenic HPV types (ABI 7500,Applied Biosystems). A separate 
quantitative real-time ß-globin control PCR was performed to evaluate DNA quality and quantity. We used 
embedded HELA-cells as a control for DNA extraction and HPV type 18 quantitative real-time PCR. All samples 
were also tested with the MY 09/11 consensus PCR. 
Results : The mean age of the younger group was 32,5 yr (95% CI 10-30), the mean age of the older group 
49,9 yr (95% CI 70-100). ß-globin was detected in 90.01% of samples. The mean amount of ß-globin was not 
signiﬁ cantly different between both groups (younger group 0.8102 ng/µL versus older group 0.7206 ng/µL). All 
samples were negative for the MY 9/11 consensus PCR. Only 1 sample (3,33%) tested positive for HPV-type 18 
in the older group and had a low viral load. 
Conclusion : HPV is present in biopsies from vas deferens. The low prevalence could be due to low ß-globin 
concentration, or because healthy asymptomatic men were included. HPV prevalence is low in asymptomatic 
healthy men. Extraction of larger amounts of DNA could increase HPV detection.
ANDROGENS REGULATION OF THE ERBB1 AND ERBB2 ONCOGENE EXPRESSION IN HUMAN PROSTATE 
CANCER CELLS.
Jean-Christophe Pignon, Laurence Delacroix, David Waltregny and Rosita Winkler
Laboratoire d’Oncologie Moléculaire, CBIG, CHU Sart-Tilman,
Tour de Pathologie, Bat B23, niv.0, B-4000 Liège
jcpignon@student.ulg.ac.be
The only efﬁ cient therapy for metastatic prostate cancer consists in androgen ablation 
that leads to regression of androgen dependent tumours. Nevertheless this response 
is temporary, and effective therapeutic regimen for tumours that became androgen 
independent is not yet available. Previous results suggest that tyrosine kinase receptors 
of the ERBB family might be implicated in prostate cancer progression towards hormone 
independence by activating the androgen receptor (AR) in androgen-depleted medium. 
In the present study, we investigated the effect of dihydrotestosterone (DHT) treatment 
on the ERBB receptors expression in two human prostate cancer cells lines, the LNCaP 
cells that express the AR and the DU145 cells that do not express the AR. 
In LNCaP cells, results of semi-quantitative RT-PCR and western blot analysis show that 
DHT treatment increases ERBB1 expression and decreases ERBB2 expression both at 
mRNA and protein levels compared with untreated cells. These effects are time and dose 
dependent. On the contrary, ERBB3 expression is not changed. No effect is observed in 
the DU145 cell line. ERBB4 is not expressed in these cells. To see if androgens inﬂ uence 
the stability of ERBB1 and ERBB2 mRNA and protein, we estimated the half-life of 
transcripts and proteins by treating LNCaP cells with respectively actinomycine D or 
cycloheximide after a DHT pretreatment. mRNA and protein expression were estimated 
by semi-quantitative RT-PCR and by western-blotting. The half-life of erbB1 and erbB2 
mRNA are respectively 6h and 10h with and without DHT. ERBB1 protein half-life is 7h 
without DHT and increases to 14h with DHT. No effect of DHT treatment was seen for 
ERBB2 protein that had a half-life of approximately 16h. 
These results strongly suggest that androgens act through a transcriptional mechanism 
to down-regulate ERBB2 transcription. For ERBB1 two mechanisms could be responsible 
for its increase, one transcriptional and the other by increase of its stability. 
In conclusion we show that DHT decreases ERBB2 expression so we could imagine that 
androgen deprivation leads to ERBB2 over-expression that could facilitate the growth 
of prostate cancer. Further experiments will be targeting to determine if androgens 
inﬂ uence ERBB2 gene transcription and by what mechanisms.
OXYGEN REGULATION OF TUMOR PERFUSION BY S-NITROSOHEMOGLOBIN: IMPLICATIONS FOR RADIOTHERAPY. 
*§Pierre Sonveaux, *Timothy J. McMahon, *Jonathan S. Stamler, §Olivier Feron, and *Mark 
W. Dewhirst.
*Duke University Medical Center, Durham, NC, USA; §Unit of Pharmacology and Therapeu-
tics (FATH5349), University of Louvain (UCL) Medical School, B-1200 Brussels, Belgium. 
(pierre.sonveaux@mint.ucl.ac.be)
Oxygen is needed to ﬁ x radiation-induced DNA damages. Several strategies have therefore 
been developed to transiently increase tumor oxygenation at the time of X-ray delivery. In this 
context, recent studies in our lab have identiﬁ ed new tumor radiosensitizing approaches. They 
encompass treatments that allow selective dilation of tumor blood vessels (e.a., by triggering 
local nitric oxide (NO) production or inhibiting the endothelin-1 vasoconstrictive pathway) 
and strategies aiming to decrease tumor cell oxygen consumption. Here, we postulated that 
another target to transiently increase oxygen delivery would be hemoglobin itself, more 
exactly the S-nitrosylated form of oxygenated hemoglobin (Hb). Indeed, while cell-free Hb 
has toxic effects (that prevent its use as a blood substitute in humans), S-nitrosohemoglobin 
(SNO-Hb) has recently been proposed to behave as a nitric oxide (NO) donor at low oxygen 
tensions. This property, in combination with oxygen transport capacity, suggests that SNO-Hb 
may have unique potential to reoxygenate hypoxic tumor tissues and, thereby, to potentiate 
the effects of ionizing radiations.
The present study was therefore designed to test the idea that the allosteric properties of 
SNO-Hb could be manipulated to enhance oxygen delivery in a hypoxic tumor and circumvent 
the Hb toxicity. Using Laser Doppler ﬂ owmetry, we showed that SNO-Hb infusion to animals 
breathing air (21% O
2
) reduced tumor perfusion without affecting blood pressure and heart 




 breathing) slowed the release of NO bioactivity from SNO-
Hb (ie, prolonged the plasma half-life of the SNO moiety in Hb), preserved tumor perfusion, 
and raised the blood pressure. In contrast, native Hb reduced both tumor perfusion and 
heart rate independently of the oxygen concentration of the inhaled gas, and did not elicit 
hypertensive effects. Dorsal skin window chamber (to image tumor arteriolar reactivity in 
vivo) and hemodynamic measurements indicated that the preservation of tissue perfusion by 
micromolar concentrations of SNO-Hb is a composite effect created by reduced peripheral 
vascular resistance and direct inhibition of the baroreceptor reﬂ ex. Overall, these results 
indicate that the properties of SNO-Hb are attributable to allosteric control of NO release 
by oxygen in central as well as peripheral issues.
In conclusion, we report here that SNO-Hb can successfully overcome the reduction in tumor 
perfusion created by Hb. Thus, the O
2
-dependent release of NO by SNO-Hb may be exploited to 
radiosensitize tumors, either directly through a decrease in tumor cell respiration or indirectly 
through vasodilation-driven reoxygenation.
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PRESENCE OF JAMESTOWN CRESTON VIRUS IN COLORECTAL MALIGNANT TUMORS: A SYSTEMATIC REVIEW 
OF PUBLISHED STUDIES THAT EMPLOYED PCR-BASED METHODS TO DETECT (JCV) IN COLORECTAL 
CARCINOMAS.
Author: Haldun Umudum MD.
Institutions : Etimesgut Air Force Hospital, Department of Pathology, Ankara, Turkey
Address for correspondance: Haldun Umudum MD, SHAPE International Military Clinic, 
Mons 07010, Belgium (humudum@yahoo.com)
Introduction : JC virus is a human polyoma virus, which is the etiologic agent of fatal 
Progressive multifocal leukoencephalopathy (PML). Recently there are reports describing 
several patients whom PML developed during the treatment with natalizumab. These 
patients were in clinical trials of natalizumab for multiple sclerosis or Crohn disease 
and the occurrence of PML was completely unexpected. These reports and subsequent 
reviews raised the question about presence of JCV in silent stage in human body. 
Futhermore several studies appeared in medical literature about the presence of JCV 
in malignant neural and colorectal tumors.
Aim of current study to evaluate the presence of JCV genome in colorectal 
neoplasms.
I searched the OVID and Pubmed databases for studies that utilized PCR based methods 
for detecting JCV in colorectal carcinoma samples.
Methods : After excluding the series that lack sufﬁ cient data, there remained eight 
studies that included 445 samples.
Results : Except one study that utilized taqman assay, all studies showed presence of 
JCV in colorectal carcinomas. Median rate of positivity was %88 (min %26, max %100). 
Two studies included adenomas (total 36 samples); rates of positivity were %4 and 
%60. While Presence of JCV in normal colon mucosa was not detected in two studies, 
another study showed 81 % positivity. One study dealt the presence of JCV in normal 
mucosa adjacent to tumor and was detected in 43 percent of samples.
Conclusion : Author believes that sufﬁ cient evidence exists for concluding that JCV 
genome presents at least in a considerable portion of colorectal neoplasms. Furthermore 
it may be concluded that normal gastrointestinal tract might serve as reservoir for JCV, 
which usually is found in raw urban sewage. We further propose that JCV as an infectious 
agent might be considered in prevention and treatment in colorectal carcinoma.
HPV DNA GENOME PRESENTS IN THE METASTASES OF LARYNGEAL SQUAMOUS CELL CARCINOMAS.
Authors: Haldun Umudum (1), Turkan Rezanko (2), Filiz Dag (2)
Institutions: 
1 Etimesgut Air Force Hospital, Department of Pathology, Ankara Turkey
2. Ataturk Training and Research Hospital, Department of Pathology, Izmir, Turkey
Address for correspondance: Haldun Umudum MD, SHAPE International Military Clinic, 
Mons 07010, Belgium (humudum@yahoo.com)
Introduction : Whereas many studies deal with the HPV and primary lesion, limited 
number of studies studied the HPV and metastatic disease in head and neck carcinomas. 
Recently HPV has been considered as causative agent of head and neck carcinomas. The 
aims of this study were to identify HPV in metastasis from laryngeal carcinoma samples 
and to describe the physical state of the viral genome to host nuclei.
Methods : Samples from metastatic lesions of primary laryngeal carcinomas were 
studied. All samples were obtained with cytological means and ﬁ xed with alcohol. 
For assessment of HPV genome presence, chromogenic ISH was performed after 
cytological review. 
Results : Integration of HPV DNA was evidently observed in 22 percent of cases. Of 
cases, ﬁ ve were from tracheostomy sites and four were from lymph nodes (3 cervical, 
1 jugular). No signiﬁ cant correlation was found between tumor differentiation and 
presence of HPV (p = 0.8). HPV genome presence was visualized as dot like signals in 
the nuclei of tumor cells. 
Conclusion : In this study we observed HPV DNA in 22 percent of metastasis of laryngeal 
carcinomas. ISH study showed a speciﬁ c punctuate pattern which has been correlated 
with DNA integration to host nuclei. As our result shown, we think HPV is also involved 
in progress to metastatic disease in a subset of laryngeal carcinomas.
WELL-DIFFERENTIATED PAPILLARY VILLOGLANDULAR ADENOCARCINOMA OF THE UTERINE CERVIX ASSOCIATED 
WITH HPV 31-33
Authors: Haldun Umudum, Almora Duman, Ahmet Goksel, Abdullah Candar
Institution: Etimesgut Air Force Hospital, Ankara Turkey
Address for correspondance: Haldun Umudum MD, SHAPE International Military Clinic, 
Mons 07010, Belgium (humudum@yahoo.com)
Background: The role of human papillomavirus in the development of squamous cell 
carcinoma of cervix (SCC) is well known, however pathogenesis of adenocarcinoma 
of cervix (ADC) is less established. Although HPV DNA is detected in >90 percent of 
SCC, HPV DNA detection rate is varied between 32 -100 percent in ADC depending on 
studies. Cervical adenocarcinomas include several different histological subtypes and 
different histological types are correlated with diverse risk factors. Minimal deviation 
ADC is associated with Peutz Jeghers Syndrome, clear cell carcinomas is correlated with 
DES exposure, serous ADC is related with its serous counterpart in endometrium. Of 
these subtypes, endocervical adenocarcinoma is related speciﬁ cally with HPV. 
Objective: We herein report a case of well-differentiated Papillary Villoglandular 
Adenocarcinoma which harbors HPV type 31-33. We investigated the HPV presence 
with chromogenic in situ hybridization and also assessed p53, Ki 67 expression in 
different component of tumor. 
Conclusion: HPV type 33 was detected in the tumor with in situ hybridization, and 
positive stains for HPV were observed in nuclei of tumor cells. Ki 67 and P53 positivity 
were observed both invasive and in situ component. We think HPV type 33 infection 
is likely contributed to the development of this tumor.
HEPATOCYTE DYSPLASIA AND TUMOR NODULE FORMATION IN CDC42-DEFICIENT MOUSE LIVER
Jolanda van Hengel1, Celine Van den Broeke1, Petra D’ hooge1, Xunwei Wu2, Cord 
Brakebusch2 and Frans van Roy1 
1Molecular Cell Biology Unit, Department for Molecular Biomedical Research, VIB-
Ghent University, Ghent, Belgium; 2Max Planck Institute for Biochemistry, Junior 
group “Cytoskeletal Organization”, Martinsried, Germany (Jolanda.vanhengel@DMB
R.ugent.be)
The small GTPase Cdc42 regulates many different aspects of cell polarity, such as axon 
formation in neurons, orientation of the Golgi apparatus in the direction of migration, 
and directed secretion to the basal side of epithelial cells. To understand the role of 
Cdc42 in the establishment and maintenance of cell polarity in vivo, we generated 
mice lacking Cdc42 expression in hepatocytes. Mutant mice were born at Mendelian 
ratios and did not exhibit increased mortality. Histological and ultrastructural analysis, 
however, revealed severe defects in livers of mutant mice. At age 3 days they showed 
dramatically enlarged canaliculi between the hepatocytes, although the tight junctions 
ﬂ anking the canaliculi appeared normal, as determined by immuno-ﬂ uorescence and 
electron microscopy. The regular liver plates were completely absent at age 2 months. 
The normally tight contacts between neighboring hepatocytes were often widened and 
the E-cadherin expression pattern was changed. Analysis of serum samples indicated 
a cholestatic phenotype characterized by at least fourfold elevated levels of alkaline 
phosphatase (AP), tenfold increased concentrations of total and conjugated bilirubin, 
and increased activities of glutamate pyruvate transaminase and glutamate oxalacetate 
transaminase (GPT/GOT). After several months we saw signs of liver transformation, 
such as hepatocyte dysplasia and nodule formation. 
We are now trying to histologically and biochemically analyze the molecular 
mechanisms underlying this phenotype, and to investigate the role of Cdc42 in tumor 
formation using a liver tumor model and partial hepatectomy.
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FARNESOL, AN INTERMEDIATE OF THE MEVALONATE PATHWAY, STIMULATES BREAST CANCER CELL GROWTH THROUGH THE ACTIVATION 
OF ESTROGEN RECEPTOR
Fabrice Journé1, Carole Chaboteaux1, Denis Nonclercq3, Guy Leclerq2, Guy Laurent3, Jean-Jacques Body1
1Laboratory of Endocrinology and Bone Diseases, 2Laboratory of Breast Cancer Research, Institut J Bordet, 
Centre des Tumeurs de l’Université Libre de Bruxelles, Brussels, and 3Laboratory of Histology, Faculty of 
Medicine and Pharmacy, Université de Mons-Hainaut, Mons, Belgium
Breast cancer is the most frequent neoplastic disease in the female population of Western countries. 
It accounts for approximately 30 percent of all diagnosed cancers and approximately 16 percent of all 
cancer-related deaths. In this clinical context, estrogen receptor (ER) expression is viewed as a reliable 
prognostic factor, highly predictive of a response to endocrine therapies. Hence, investigations of the 
mechanism controlling ER levels and activities are of prominent importance. ER acts as an estrogen-
modulated transcription factor and can also mediate ligand-independent transcription via crosstalks with 
growth factors signaling. Moreover, ER may also be a membrane-associated receptor, able of eliciting both 
genomic and non-genomic responses.
Farnesol (FOH) is a metabolic intermediate of the mevalonate pathway leading to cholesterol synthesis and 
protein prenylation. It can also bind to farnesoid X receptor (FXR, NR1H4), a member of the superfamily of 
nuclear receptors / transcription factors that classically heterodimerizes with retinoid X receptors (RXR). 
FXR is involved in cholesterol metabolism regulation and bile acid transport in liver and gastrointestinal 
tract, and could be related to cardiovascular diseases. Surprisingly, it is also found in a number of different 
metastatic cancers.
We assessed the effects of FOH on ER-positive MCF-7 breast cancer cells cultured in steroid-free medium. 
FOH (50 µM) increased by up to two-fold the growth of MCF-7 cells in a dose-dependent manner, while it 
had no effects on the ER-negative MDA-MB-231 cells (crystal violet staining assay). In addition, both partial 
(4-hydroxytamoxifen) and pure antiestrogens (ICI 182,780) completely suppressed the mitogenic effects 
of FOH in MCF-7 cells, suggesting that they were mediated by activation of ER. Indeed, as documented 
by Western blot and immunoﬂ uorescence, FOH downregulated ER. In these conditions, ER degradation 
was inhibited by 4-hydroxytamoxifen. FOH also stimulated the transcription of an estrogen-responsive 
reporter gene, pointing to an estrogenic effect of FOH on MCF-7 cells. In order to explore the mechanism 
of FOH-induced ER activation, we detected FXR protein in MCF-7 cells, both by Western blot (~60kDa) 
and immunoﬂ uorescence. We are currently looking for the possible occurrence of FXR-ER complexes (ER 
immunoprecipitation and FXR immunoblot). In addition, other experiments are ongoing to inhibit FXR 
expression in MCF-7 cells by using FXR siRNA. Use of these FXR-null cells would deﬁ nitely establish 
the involvement of this nuclear receptor in the activation of ER by FOH and in FOH-induced mitogenic 
effects.
In conclusion, our study demonstrates for the ﬁ rst time that FOH stimulates MCF-7 cells proliferation 
through the activation of ER. We speculate that ER activation could occur through FXR-ER heterodimeri-
zation. Thus, FOH, an important intracellular metabolite, could contribute to the basal stimulation of 
ER in breast cancer cells. Inhibition of FOH production by using inhibitors of the mevalonate pathway 
(nitrogen-containing bisphosphonates or statins) could reduce FOH-induced ER activation and ER-
mediated cancer cell growth.
PROTEOMIC PROFILING TO SEARCH FOR NEW BIOMARKERS OF TUMOR-INDUCED OSTEOLYSIS
Fabian Place1, Fabrice Journé1, Carole Chaboteaux1, Naïma Kheddoumi1, Ruddy Wattiez2, Jean-Jacques Body1
1Laboratory of Endocrinology and Bone Diseases, Institut J Bordet, Centre des Tumeurs de l’Université Libre de 
Bruxelles, Brussels, Belgium
2Department of Biological Chemistry and Proteomy, Faculty of Sciences, Université de Mons-Hainaut, Mons, 
Belgium
The proteomic analysis, two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) coupled with mass 
spectrometry analysis (MS), allows the assessment of protein proﬁ les by simultaneously examining the expression 
of hundreds to thousands of proteins. It may determine all coordinated changes at protein levels between clinical 
groups to generate clusters of markers representative of speciﬁ c cell functions. This technology should be a useful tool 
for protein proﬁ ling of clinical specimens to search for new biomarkers of tumor-induced osteolysis in serum from 
patients with bone metastases from breast cancer.
The 2D-PAGE allows the separation of a complex protein mixture from tissues, cells or biological ﬂ uids. Serum 
is a common source of proteins for 2D electrophoresis because of its very high protein and low salt concentra-
tions, simplifying sample preparation (critical part of 2D-PAGE). However, the major drawback of serum samples 
is the high proportion of albumin (Alb) and immunoglobulin (IgG), which can reach 90% of the total protein 
content. These major proteins could occult minor proteins, which can be potential candidate biomarkers. In a 
previous study, we have reported the interest and efﬁ ciency of depletion of Alb/IgG from serum samples prior to 
2D-PAGE by the comparison of 2D gels of native and depleted serum samples from 20 healthy premenopausal 
women. The depletion step increases the detection of weakly expressed proteins and therefore provides better 
conditions for the search of novel biomarkers.
In order to search for new biomarkers of bone resorption due to metastatic cancer cells, we compared serum 
protein expression proﬁ les from patients with breast carcinomas with or without bone metastases. We analyzed 
Alb/IgG depleted serum by 2D-PAGE and detected several protein spots in the bone metastasis group. Preliminary 
analysis suggests that this set of spots includes ceruloplasmin, a protein known to be involved in metastatization 
process. Other protein changes are under MS analysis.
In addition, in order to study the possible direct resorption of bone by cancer cells, we developed an in vitro 
model of tumor-induced osteolysis by culturing MDA-MB-231 breast cancer cells on bovine dead bone slices. A 
classical bone resorption marker (the telopeptide CTx) could be detected in the culture medium of MDA-MB-
231 cells cultured on bone slices. We are currently searching for potential new biomarkers of bone resorption 
released into the culture medium.
Moreover, this in vitro study permitted to examine the effects of bone matrix components on the MDA-MB-231 
cell proteome. In a pilot study, we detected many changes in protein expression proﬁ les between MDA-MB-231 
cells cultured on bone slices as compared with incubation on plastic dishes. Signiﬁ cant changes are currently 
under analysis by MS.
In conclusion, current knowledge emphasizes the necessity to investigate tumor-induced osteolysis through a 
more global comprehensive approach as provided by proteomic analysis that allows the detection of variations 
of many factors. Proteomic proﬁ ling of serum from breast cancer patients without metastases versus patients 
with bone metastases could reveal critical biomarkers related to bone degradation directly mediated by breast 
cancer cells.
IN VITRO DIFFERENTIATION OF HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS TOWARDS THE OSTEOBLAST LINEAGE. 
A MODEL TO STUDY THE EFFECTS OF CANCER CELLS ON BONE FORMATION.
Hichame Id Boufker1, Fabrice Journé1, Laurence Lagneaux2, Tatiana Tondreau2, Jean-Jacques Body1
1Laboratory of Endocrinology and Bone Diseases, 2Laboratory of Experimental Hematology, Institut 
J Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles, Brussels
Breast carcinoma has a high predisposition to metastasize to bone and to induce a marked osteoclast-
mediated bone destruction. However, osteoblasts indirectly participate in the process of tumor-induced 
osteolysis. Tumor cells can activate osteoclasts notably through the secretion of PTHrP that acts on 
osteoblasts and increase RANKLigand expression that will induce osteoclast differentiation and activity. 
Osteoblasts are actually pivotal cells for the control of bone turnover. Immature osteoblasts regulate the 
differentiation and the activity of osteoclasts, while mature osteoblasts produce bone matrix (collagen 
synthesis and mineralisation).
Human bone marrow-derived mesenchymal stem cells (MSC) are pluripotent progenitor cells that can be 
differentiated into many mesenchymal lineages, including chondroblasts, adipocytes or osteoblasts, by 
appropriate stimulations. The effect of cancer cells on osteoblast differentiation is unknown.
MSC were isolated from fresh healthy bone marrow specimens and identiﬁ ed by expression of SH2 
and SH3 antigens and the absence of CD45 antigen. Undifferentiated MSC are expanded in αMEM 
supplemented with 20% FCS without any change in their differentiation potential. MSC were incubated 
with dexamethasone, ascorbic acid and β-glycerophophate-enriched medium (DAG) to induce MSC 
differentiation towards the osteoblast lineage.
MSC obtained from 9 donors were incubated in DAG medium during the ﬁ rst four passages. At each 
passage, MSC were examined after 7, 14 and 21 days of incubation. Alkaline phosphatase (ALP) activity, 
a classical marker of osteoblastic lineage was reliably increased in MSC incubated with DAG. The increase 
was already detectable at day 7 (3.3 fold versus untreated MSC), reached a maximum after 14 days of 
DAG stimulation (10.6 fold) and decreased after 3 weeks of culture (6.5 fold). The increase in ALP activity 
was low in MSC tested after the ﬁ rst passage, became signiﬁ cant after the second passage and dropped 
after the fourth passage. In addition, cell-mediated matrix mineralization was determined by von Kossa 
staining. After the ﬁ rst cell passage, DAG medium stimulated calcium deposition at day 14 and even more 
at day 21 (15.9 and 24.8 fold versus untreated MSC, respectively) in MSC from two thirds of the donors 
(6/9). After the second passage, DAG-stimulated matrix mineralization was observed in MSC from nearly 
all donors (8/9), again at days 14 and 21. However, after the fourth passage, matrix mineralization was 
stopped in all MSC tested, indicating the loss of differentiation potential of these cells. Furthermore, we 
are currently testing and comparing several other osteoblastic markers, assessing the expression of genes 
for early (type I collagen), middle (ALP), and late (osteopontin, osteocalcin, PTH receptor) differenciation 
markers of the osteogenic lineage by semi-quantitative RT-PCR. We thus observed a 3-fold increase in 
ALP and osteopontin mRNA in MSC already after 7 days of culture in DAG medium, while PTH receptor 
was increased for more than 7 fold only after 21 days.
In conclusion, this study describes an in vitro model of DAG-induced osteogenic differentiation of bone 
marrow mesenchymal stem cells, using various osteoblastic markers. Our data indicate the need of use 
MSC during the second and third cell passages. Human MSC should constitute a useful in vitro tool to 
study the effects of osteotropic cancer cells on osteoblast differentiation and to better understand the 
reduced bone formation in the process of tumor-induced osteolysis.
ANALYSIS OF MICE LACKING P120 CATENIN EXPRESSION IN HEPATOCYTES
Céline Van den Broeke1, Petra D’ hooge1, Albert Reynolds2, Frans van Roy1 and Jolanda 
van Hengel1
1Molecular Cell Biology Unit, Department for Molecular Biomedical Research, VIB-Ghent 
University, Ghent, Belgium; 2Department of Cancer Biology, Vanderbilt University, 
Nashville, TN, USA.
Acquisition of invasive and metastatic capabilities is frequently associated with loss 
of cell-cell adhesion. One of the major constituents of the cell-adhesion complex in 
epithelial cells is E-cadherin, a transmembrane protein involved in homotypic cell-cell 
adhesion. The p120 catenin (p120ctn) protein is a member of the Armadillo-protein 
family and also a key component of the adherens junctions, where it interacts at the 
juxtamembrane site with the cytoplasmic tail of the cadherins. New evidence indicates 
that p120ctn acts as an essential surface retention signal for cadherins and participates 
directly or indirectly in trafﬁ cking decisions that control cadherin turnover at the cell 
surface. The p120ctn level acts as a sensor of cadherin levels, providing a crucial rheostat 
or set point mechanism controlling cadherin availability. E-cadherin is generally known 
as a tumor and/or metastasis suppressor, depending on the mechanism and timing of 
E-cadherin downregulation.
By crossing mice with a ﬂ oxed p120ctn allele with albumin-Cre mice, we generated mice 
lacking p120ctn expression speciﬁ cally in hepatocytes. Although mice lacking p120ctn in 
other organs generally display an embryonic or postnatal lethal phenotype, our mutant 
mice were born at Mendelian ratios and stayed alive for at least ﬁ ve months. 
The liver-speciﬁ c p120ctn KO mice showed an increased liver weight. In those livers a 
ductular reaction was observed on H/E stainings. Immunostaining showed a changed 
E-cadherin expression proﬁ le and reduced N-cadherin levels. Analysis of serum samples 
indicated elevated levels of alkaline phosphatase (AP) and tenfold increased concentra-
tions of total and conjugated bilirubin, whereas glutamyl pyruvic transaminase (GPT) 
and glutamyl oxaloacetic transaminase (GOT) levels remained unchanged. 
Further analysis of the in vivo roles of p120ctn in the liver and of the possible relevance 
of its loss for the causation of hepatocellular carcinoma (HCC), one of the most common 
solid tumors worldwide, is in progress.
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THYROTROPIN-STIMULATED PRIMARY THYROID CELL CULTURES AS A MODEL OF BENIGN THYROID TUMORS: 
A MICROARRAY ANALYSIS
W.C.G. van Staveren*, D. Weiss Solís, L. Delys, G. Andry, D. Dequanter, M. Cappello, F. 
Libert, V. Detours and C. Maenhaut
Institute of Interdisciplinary Research (IRIBHM) and Jules Bordet Institute, Free University 
of Brussels, 808 route de Lennik, 1070 Brussels, Belgium.
In a large number of tumors from various origin, mutations have been detected in genes 
that are involved in the normal regulation of cell division. Since these genes play a 
critical role in the decision of the cell to divide, they are putative oncogenes and anti-
oncogenes. In the thyroid, cell growth and proliferation are induced by the binding of 
thyrotropin (TSH) to the TSH receptor, which leads to the activation of the cyclic AMP 
(cAMP) signaling cascade. Previous research has shown that mutations in components 
of the cAMP-cascade promote unrestrained growth in thyroid cells, resulting in the 
formation of benign thyroid tumors. In this study, primary culture of human thyrocytes 
were used as a model to search for genes that might be involved in the induction 
and promotion of a thyroid tumor. Cultures were treated with TSH to investigate the 
proliferative intracellular signaling pathways that are triggered by this hormone. Gene 
expression proﬁ ling was performed by cDNA microarray analysis (23,232 spots) after 
stimulation of the cultures for different times (1.5 hours, 3 hours, 16 hours, 24 hours 
and 48 hours). Comparison of gene expression in primary cultures in the presence or 
absence of TSH demonstrated an upregulation and downregulation of a large number 
of spots at all the time points investigated. The reproducibility of the experiments was 
high: duplicate microarrays, intensity ratios of different spots corresponding to the 
same genes on the same microarray, as well as the kinetic evolution, was consistent 
throughout different experiments. The pattern of expression shows an early shift in 
the transcription factors and signal transduction proteins expressed, i.e. a change of 
cell program. Later changes reﬂ ect a stimulation of speciﬁ c cell functions and a trophic 
effect. This pattern of late changes reﬂ ects in part the pattern of autonomous adenomas. 
A number of genes were selected to conﬁ rm modulation by using real time PCR. To 
conclude, primary culture of human thyrocytes stimulated with TSH gives insight in the 
signaling pathways that are involved in mitogenic cell signaling and provides a model 
for autonomous adenomas.
* presenting author
 e-mail address: wvstaver@ulb.ac.be
GENE EXPRESSION IN THYROID PAPILLARY CARCINOMAS.
L. Delys, V. Detours, D. Dequanter, G. Andry, C. Menhaut
IRIBHM and Institut Bordet, University of Brussels.
Thyroid tumors are the most frequent endocrine tumors. The major phenotypes are the 
benign adenomas, autonomously hyperfunctioning or not, and the malignant carcino-
mas. The main malignant thyroid tumors are subdivided in follicular or papillary (PTCs) 
carcinomas, still partly differentiated, and both of which may evolve in anaplastic 
carcinoma, totally dedifferentiated. There has been a considerable increase in thyroid 
cancer after the Chernobyl nuclear power plant accident. These thyroid cancers have 
been identiﬁ ed as PTCs on the basis of their pathology. The Chernobyl accident therefore 
provides a unique opportunity to characterize radiation-induced thyroid cancer. 
The aim of this work was to characterize the molecular proﬁ le of PTCs, using the 
cDNA microarray technology, and to ask whether the post-Chernobyl PTCs could be 
distinguished from sporadic PTCs, ie. if both have the same molecular phenotype. 
A molecular signature allowing to separate both types of PTCs is presented and 
discussed. 
